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Abstract 
 
 
Colorectal cancer is among four most common malignancies and the second leading 
cause of cancer death in the western world. Although the standard treatment regimens 
have improved the prognosis, resistance to cytotoxic chemotherapy is still a common 
problem in these patients and a major obstacle to effective treatment of disseminated 
neoplasms. The subject of this study was to evaluate a possible role of anthocyanidins, 
natural products belonging to the group of flavonoids, in the treatment of colorectal 
cancer. Primary (CACO-2) and metastatic human colorectal carcinoma cell lines (LoVo 
and LoVo ADR) were used to test different aspects of their pharmacological effect, such 
as their ability to affect cancer cell growth and to modulate the cytotoxicity of certain 
well established anticancer drugs. Their proapototic properties, as well as their capacity 
to induce changes in the cellular redox status and modulate drug transport mechanisms 
were also explored.  
        The anthocyanidins used in this study, delphinidin and cyanidin, demonstrated 
strong cytotoxic effect in metastatic human colorectal cancer cell lines, LoVo and LoVo 
ADR, and were able to modulate the cytotoxicity of camptothecin, drug used in most 
colorectal cancer treatment regimes. Although well known for their antioxidant properties 
and lower toxicity in normal cells, delphinidin and cyanidin showed strong prooxidant 
activity in the metastatic colon carcinoma cell lines. We show that anthocyanidins 
inactivate the glutathione antioxidant system thus promoting oxidative stress in these 
cells, which might be responsible for their proapoptotic activity. Moreover, when applied 
at low, non-cytotoxic concentrations over a long period of time, they also affect 
anticancer drug transport across cell membranes by modulating expression of certain 
transport proteins (ABC transporters). These results suggest that anthocyanidins can be 
good candidates for improving colorectal cancer therapy and warrant new investigation 
on their activity.   
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                                                                            Hippocrates (ca. 460 BC – ca. 370 BC) 
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1. Introduction 
 
 
 
1.1. Cancer statistics 
 
 
Cancer is a growing health problem around the world, particularly with the steady rise in 
life expectancy, increasing urbanization and the subsequent changes in environmental 
conditions, including lifestyle (poor diet and lack of exercise). According to the World 
Health Organization (WHO), there are now more than 10 million new cases of cancer per 
year worldwide and this number is on the increase. Experts predict that if current trends 
continue, there will be a 50 percent increase in incidence between 2000 and 2020 with 
well over 15 million new cases a year diagnosed in 2020. The WHO report and 
estimation for 2008/2009 claims over 12 million people diagnosed with cancer (1). It was 
estimated that in 2008 there would be 1,437,180 new cancer cases (745,180 in men and 
692,000 in women) and 565,650 cancer deaths (294,120 among men and 271,530 among 
women) in the United States (2). With an estimated 3.2 million new cases (53% occurring 
in men, 47% in women) and 1.7 million deaths (56% in men, 44% in women) each year, 
cancer remains an important public health problem in Europe as well (3). The ageing of 
the European population will cause these numbers to continue to increase even if age-
specific rates remain constant.  
 
 
1.2. Colorectal cancer 
 
Colorectal cancer is the fourth most common malignancy in the United States and the 
second most frequent cause of cancer-related death. It was estimated that in 2008 148.810 
cases of colorectal cancer (108.070 colon, 40.740 rectal) would be diagnosed and 49.960 
people would die from the disease in the United States (2). In Europe, however, 
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colorectal cancer ranks second in both incidence and mortality (3). On the other hand, it 
is rare in Asia and Africa.  
 
        Genetics, experimental, and epidemiological studies suggest that colorectal cancer 
results from complex interactions between inherited susceptibility and environmental 
factors. Factors that increase a person's risk of colorectal cancer include high fat intake, a 
family history of colorectal cancer and polyps, the presence of polyps in the large 
intestine, and chronic ulcerative colitis.  
        Diets high in fat are believed to predispose humans to this type of cancer. In 
countries with high colorectal cancer rates, the fat intake by the population is much 
higher than in countries with low cancer rates. Dietary fat increases bowel transit time 
and increases the concentration of fecal bile acids, such as cholic and deoxycholic acid. 
These bile acids act as potential carcinogens on the colonic mucosa. In contrast to fat, 
fiber decreases bowel transit time and therefore exposure of the bowel to these 
carcinogens. Therefore, a diet rich in carbohydrates, fruits, and fiber may bestow a 
protective effect from cancer development. (4,5). 
        Most cases of colon cancer begin as small, noncancerous (benign) clumps of cells 
called adenomatous polyps (Fig. 1). If not removed, these polyps can acquire additional 
chromosome damage and become cancerous over time (Fig. 2). Colon cancer can invade 
and damage adjacent tissues and organs. Cancer cells can also break down and spread to 
nearby lymph nodes (local metastasis) and subsequently to more remote lymph nodes and 
other organs in the body. The liver and the lung are common metastatic sites of colorectal 
cancer. Once metastasis has occurred, a complete cure of the cancer is unlikely (6).  
        The most common colon cancer cell type is adenocarcinoma (cancer that begins in 
cells that make and release mucus and other fluids), which accounts for 95% of cases.  
        Colon cancer can be present for years before symptoms occur. They can be 
numerous and nonspecific, including fatigue, weakness, shortness of breath, change in 
bowel habits, narrow stools, diarrhea or constipation, red or dark blood in stool, weight 
loss, abdominal pain, cramps, or bloating. Symptoms vary according to where in the large 
intestine the tumor is located. Cancers of the right colon can grow to large sizes before 
they provoke abdominal symptoms, and usually cause iron deficiency anemia. The 
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cancers of the left colon, which is narrower than the right colon, are more likely to cause 
partial or complete bowel obstruction followed by abdominal symptoms.  
 
 
 
 
 
 
 
 
  
                                                      
                                              
                                               
 
        Since colon cancer can take many years to develop, early detection can greatly 
improve the chances of a cure. There are several screening tests available, including fecal 
occult blood tests (FOBTs), flexible sigmoidoscopy, double-contrast barium enema, and 
colonoscopy. Screening for the disease is recommended in all men and women aged 50 
years or older and all individuals who are at increased risk (7). 
        Prognosis for patients depends on the spread of the cancer, i.e. its pathologic stage at  
diagnosis. The tumor-node-metastasis (TNM) system, as defined by the American Joint 
Committee on Cancer (AJCC), is the most commonly used staging system and is based 
on depth of invasion of the bowel wall, extent of regional lymph node involvement, and 
presence of distant sites disease (Table 1). As the AJCC stage increases from stage I to 
stage IV, the 5-year overall survival rates decline dramatically: stage I, greater than 90%; 
stage II, 70%–85%; stage III, 25%–80%; and stage IV, less than 10% (8). On average, 
patients survive for 3 years after diagnosis. Median survival after diagnosis of metastatic 
disease is approximately 6–9 months. The 5-year survival rate for advanced colorectal 
cancer is lower than 5% (6). 
 
Figure 1. The inside of the colon: two small 
polyps whose diameters are about the size of a 
pencil eraser (about 6 to 7 millimeters). (Mayo 
Foundation for Medical Education and Research) 
 
Figure 2. The inside of the colon: colon 
cancer (Mayo Foundation for Medical Education 
and Research) 
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                Table 1. TNM Staging System for Colorectal Cancer (data from ref. 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
    About 80% of patients diagnosed with colorectal cancer undergo surgery. Many of 
them have potentially good survival outcomes (with adjuvant chemotherapy in some 
cases), but over 50% of those who have undergone surgery with apparently complete 
excision will eventually develop advanced disease and distant metastases (typically 
presenting within 2 years of initial diagnosis). The liver reflects the most common initial 
site of disease spread, but metastases to other organs during the course of the disease are 
common, including to the lungs, peritoneum, and intra-abdominal lymph nodes. Patients 
with a small number of isolated, organ-confined metastases may be cured of their disease 
by surgical resection (10). Most patients with metastatic disease are candidates for 
systemic chemotherapy to palliate symptoms and prolong life.  
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1.3. Chemotherapy 
 
Chemotherapy is used to reduce the likelihood of metastasis developing; shrink tumor 
size, or slow tumor growth.  
 
Fluorouracil (5-FU) remains the cornerstone of systemic treatment for colorectal cancer. 
It is a fluorinated pyrimidine that acts primarily through inhibition of thymidylate 
synthetase, the rate-limiting enzyme in pyrimidine nucleotide synthesis and is commonly 
administered with leucovorin, a reduced folate that is thought to stabilize fluorouracil's 
interaction with this enzyme (11). Fluorouracil can be administered by a variety of 
different schedules, with differing toxicity profiles. Neutropenia and stomatitis are the 
most frequent side effects when bolus fluorouracil and leucovorin are administered daily. 
Higher rates of diarrhea are noted when bolus fluorouracil and leucovorin are 
administered weekly. Schedules that administer fluorouracil as a continuous infusion are 
associated with less hematologic and gastrointestinal toxicity, but have a greater 
incidence of hand-foot syndrome, a tender, erythematous rash involving the palms and 
soles (9). 
        Fluorouracil-based chemotherapeutic regimens are standard treatment for patients 
with colorectal cancer. However, response rates for 5-FU as a single first-line treatment 
in advanced colorectal cancer are only 10-15% (12). Combining 5-FU with the newer 
chemotherapeutics, irinotecan and oxaliplatin, has improved response rates for advanced 
colorectal cancer to 40-50%, and increased median survival for these patients from about 
12 months with fluorouracil alone to 24 months or higher (13, 14). The use of novel 
biological agents, such as monoclonal antibodies, cetuximab and bevacizumab, have 
recently been shown to provide additional clinical benefit.   
 
Irinotecan, combined with fluorouracil and leucovorin, has been shown to be beneficial 
in the treatment of colorectal cancer (15). Irinotecan is a semisynthetic derivative of the 
natural alkaloid camptothecin that was first isolated from the bark of the Chinese tree, 
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Camptotheca acuminata. This compound was first identified in 1966 in a screen of plant 
extracts for antineoplastic drugs (16, 17). Subsequently, many derivatives of the parent 
compound have been synthesized and two have been approved for clinical use, topotecan 
(for the treatment of metastatic ovarian and small cell lung cancer) and irinotecan 
(approved for use in the treatment of metastatic colorectal carcinomas) (18). Irinotecan 
(CPT-11) is a prodrug which is converted to the active compound SN-38 by plasma and 
cellular carboxylesterases. By inhibiting topoisomerase I, an enzyme that catalyzes 
breakage and rejoining of DNA strands during DNA replication, irinotecan causes 
irreversible double-strand DNA break that ultimately leads to DNA fragmentation and 
programmed cell death (19). Metabolism of irinotecan occurs predominantly in the liver, 
where it is inactivated by glucuronidation and excreted through the biliary system. The 
most commonly observed toxicities associated with irinotecan are diarrhea, 
myelosuppression, and alopecia (9). 
Oxaliplatin is a diaminocyclohexane platinum compound that forms platinum adducts on 
DNA (among which Pt-GG and Pt-AG intra-strand crosslinks are the major lesions), 
leading to impaired DNA replication and transcription and cellular apoptosis (20). In 
patients with metastatic colon cancer, single-agent oxaliplatin has limited efficacy, but 
clinical benefit has been observed when it is administered with fluorouracil and 
leucovorin, possibly as a result of oxaliplatin-induced down-regulation of thymidylate 
synthetase; namely, sequential administration of oxaliplatin followed by 5-FU results in a 
significant decrease in thymidylate synthase gene expression which opens up the 
possibility of reacquired 5-FU sensitivity (21). A cumulative sensory neuropathy, 
characterized by paresthesias of the hands and feet, is the primary toxicity associated with 
oxaliplatin. 
The use of novel biological agents, the monoclonal antibodies bevacizumab (a vascular 
endothelial growth factor inhibitor) and cetuximab (an epidermal growth factor receptor 
inhibitor) has been shown to provide additional beneficial effects for patients with 
metastatic colorectal cancer.  These agents are now under intense investigation in the 
adjuvant setting. Despite their efficacy rare, yet serious side effects have been observed 
(22, 23). 
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Although the abovementioned agents have proven to be effective, improving response 
rates and increasing the median survival of patients with advanced colorectal cancer, 
modern medicine still faces a critical clinical problem- drug resistance, and needs new 
therapeutic strategies.  
 
 
 
1.4. Drug resistance 
 
Resistance to cytotoxic chemotherapy is a common problem in patients with cancer and a 
major obstacle to effective treatment of disseminated neoplasms. Some cancers such as 
non-small cell lung cancer, and rectal cancer show what is called primary, natural or 
intrinsic resistance in which they do not respond to standard chemotherapy drugs from 
the beginning. On the other hand, many types of sensitive tumors respond well to 
chemotherapy drugs in the beginning but show acquired resistance later (24). 
Experimentally, drug resistance could be very specific to the drug used due to abnormal 
genetic machinery such as gene amplification within tumor cells in many cases.  
           Multidrug resistance (MDR) is especially problematic in acquired drug 
resistance. MDR is the phenomenon in which cancer cells exposed to one anticancer drug 
show cross-resistance to other structurally and functionally unrelated drugs. This might 
explain why treatment regimens that combine multiple agents with different targets are 
not always more effective. 
           There are two general classes of resistance mechanisms: those that impair delivery 
of anticancer drugs to tumor cells, and those that arise in the cancer cell itself due to 
genetic and epigenetic alterations that affect drug sensitivity. Impaired drug delivery 
can result from poor absorption of orally administered drugs, increased metabolism or 
increased excretion, resulting in lower levels of drug in the blood and reduced diffusion 
of drugs from the blood into the tumor mass (25).  
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                      Figure 3.  Cellular factors that cause drug resistance  
                                          (taken from Gottesman  MM. (26)).  
 
Cellular mechanism of multidrug resistance include: a) activation of transmembrane 
ATP-dependent proteins with broad drug specificity, that efflux chemical substances 
from the cells lowering their intracellular concentration; b) activation of coordinately 
regulated detoxifying systems, such as the glutathione system and the cytochrome P450 
mixed function oxidases; c) alterations of the genes and the proteins involved in the 
control of apoptosis (especially p53 and Bcl-2) (26, 27, Fig. 3). 
        An important principle in multidrug resistance is that cancer cells are genetically 
heterogenous. Although the process that results in uncontrolled cell growth in cancer 
favors clonal expansion, tumor cells that are exposed to chemotherapeutic agents will be 
selected for their ability to survive and grow in the presence of cytotoxic drugs. These 
cancer cells are likely to be genetically heterogeneous because of the mutator phenotype. 
So, in any population of cancer cells that is exposed to chemotherapy, more than one 
mechanism of modulating resistance can be present. This phenomenon has been called 
multifactorial multidrug resistance (26).   
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1.4.1. ABC transporter proteins 
 
ABC protein history is rooted in bacterial substrate transport studies beginning in the 
1960s. Several mechanisms for substrate transport were described, among which binding 
protein-dependent (BPD) systems (28). A decade later, in 1974, Berger and Heppel (29) 
demonstrated that the energy for transport in BPD systems required ATP. In the years 
that followed scientists managed to identify nucleotide sequences of multiple BDP 
transporters that bind ATP and to demonstrate ATP-hydrolysis. These discoveries led to 
the recognition of BDP transporters as a superfamily of ATP-dependent transporters (30). 
        The two highly conserved nucleotide-binding domains (NBDs) define the 
membership to the ABC protein superfamily. Substrate recognition, on the other hand, is 
a function of the trans-membrane domains (TMDs), and sequence and protein 
homologies in this region define which subfamily the ABC proteins belong (31). ABC 
proteins are classified in seven subfamilies: ABCA (ABC1), ABCB (MDR), ABCC 
(CFTR/MRP), ABCD (ALD), ABCE (OABP), ABCF (GCN20) and ABCG (WHITE).  
        The first human ABC transporter to be discovered was ABCB1 (P-glycoprotein or 
MDR1) in 1976. Since then, 47 additional ABC proteins have been identified in the  
 
 
                                                       Figure 4.   P-gp 
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                                                       Figure 5.   MRP-1 
 
 
 
 
 
 
 
 
 
                                                       Figure 6.  BCRP 
 
human genome. The number of TMDs varies from two to free for most members of the 
ABC superfamily (Fig. 4, 5, 6). Yet, some of the new members of the ABC superfamily 
do not contain TMDs, and therefore they may not be involved in transport. This category 
comprises ABCE and ABCF subfamilies for which functions remain unclear. 
        In normal physiology, these proteins are often expressed to the greatest extent in the 
tissues that require special protection from chemical assaults, such as liver, intestines and 
kidney (32). ABCB1 (MDR1, P-gp) protein (a 170 kDa protein) is highly expressed in 
adrenal gland and kidney, but is also found in colon, liver and small intestine. ABCC1 
(MRP1) (190kDa) is expressed at moderate levels in most normal tissues, except the 
liver where it is usually barely detectable, whereas in skeletal muscles and prostate was 
found to be expressed to the greatest extent; on the other hand, ABCC2 (MRP2) is 
highly expressed in liver and kidney, as well as ABCC3 (MRP3) whose high expression 
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levels have been also reported in colon, stomach, adrenal gland and pancreas, and 
ABCC4 (MRP4) that is also found in prostate, skeletal muscles, and testis. ABCG2 
(BCRP) (72kDa) is moderately expressed in placenta but was found in liver, lung and 
adrenal gland as well (32, 33).  
        The importance of ABC transporters expression in normal tissues has proven 
significant. Many important endogenous compounds such as nucleotides, folate, steroids 
and eicosanoids rely on ABC transporters to be secreted. Their importance in xenobiotic 
detoxification is also well established. The heart represents an example where low 
expression of ABC transporters likely limits its ability to respond to exogenous chemical 
insults. Cardiotoxicity often dictates safety margins for the use of chemotherapeutics such 
as the anti-cancer agent doxorubicin.  
        The important role of ABC transporters in responding to environmental and 
biological assaults can, however, create a problem for cancer chemotherapy, since cancer 
cells have the ability to develop resistance to therapeutics by over-expressing some of 
these transporters. The majority of transporters that confer a drug resistant phenotype 
were first called multi-drug resistant proteins (MRPs) and later classified as members of 
the ABCC subfamily. This subfamily includes ABCC1 (MRP1), ABCC2 (MRP2), 
ABCC3 (MRP3), ABCC4 (MRP4), ABCC5 (MRP5), ABCC6 (MRP6), ABCC10 
(MRP7), ABCC11 (MRP8), and ABCC12 (MRP9). ABCB1 (MDR1, P-glycoprotein) 
and ABCG2 (BCRP) are also known for imparting a multidrug resistance phenotype (34). 
Interestingly, three ABC genes appear to account for nearly all of the MDR tumor cells in 
both human and rodent cells: P-gp, MRP1 and BCRP (35). The substrates that these 
transporters recognize are very diverse in structure. MRP1 alone recognizes dozens of 
naturally occurring and synthetic compounds (36, Table 2). 
        The expression profile of ABC transporters in tumors is, similarly to normal tissues, 
highly variable, both between tumor families as well as within tumor families (Table 3).  
         Yet, ABC transporters expression in cancer cells remains largely unpredictable. 
Clinical studies suggest that cancer cells adapt better to chemical insults than normal cells 
due, in part, to their ability to rapidly modulate their ABCs in response to multiple stimuli 
(37). 
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 Table 2  - ABC genes with associated drug resistance phenotypes (readapted from Leitner H.et    
                      al.(33))  
 
Gene name 
(common names) 
Substrates                                    Drug resistance and/or 
disease 
phenotypes 
Glutathione 
transport 
ABCB (MDR/TAP) 
ABCB1 (PGY1, PG-P, 
MDR1, GP170) 
Colchicine, doxorubicin, 
vinblastine, 
digoxin, saquinivir, 
paclitaxel, 
verapamil, PSC8233, 
GG918, 
V-104, Pluronic L61 
Multidrug resistance 
phenotype, 
ivermectin susceptibility, 
digoxin 
uptake, HIV protease 
inhibitor resistance 
 
Unknown 
 
ABCC (CFTR/MRP) 
ABCC1 (MRP1, MRP, 
ABCC, GS-X, ABC29) 
 
Doxorubicin, 
daunorubicin, 
vincristine, colchicines, 
etoposide, rhodamine, 
cyclosporin A, V-104 
Multidrug resistance 
phenotype 
GSH and GSH S-
conjugates 
are transported. Some 
substrates stimulate GSH 
transport without being 
transported themselves 
ABCC2 (MRP2, cMOAT) Vinblastine, 
sulfinpyrazone, 
etoposide, cisplatin 
 
Multidrug resistance 
phenotype, 
Dubin–Johnson 
syndrome 
GSH and GSH S-
conjugates 
are transported 
 
ABCC3 (MRP3) Methotrexate, etoposide Multidrug resistance 
phenotype 
GSH S-conjugates are 
transported 
ABCC4 (MRP4) Cyclic nucleotides, 
prostaglandins, 
antiretrovirals, purine 
analogs 
Multidrug resistance 
phenotype, 
nucleoside/tide reverse 
transcriptase inhibitor 
resistance 
GSH and GSH S-
conjugates 
are transported 
 
ABCC5 (MRP5) Cyclic nucleotides, 
antiretrovirals, 
purine analogs 
Multidrug resistance 
phenotype 
GSH and GSH S-
conjugates 
are transported 
 
ABCC6 (MRP6) Leukotriene C4, 
N-ethylmaleimide-GSH 
 
Mutated in 
Pseudoxanthoma elasticum 
Conflicting data about 
transport of GSH S-
conjugates 
ABCC10 (MRP7) Glucuronate conjugates, 
leukotriene C4 
Multidrug resistance 
phenotype 
Unknown 
 
ABCC11 (MRP8) Cyclic nucleotides Unknown physiological 
role 
Unknown 
ABCC12 (MRP9) Unknown Associated with 
paroxysmal 
kinesigenic 
choreoathetosis 
Unknown 
 
ABCG2 (BCRP, 
MXR1, ABCP) 
Mitoxantrone, topotecan, 
doxorubicin, 
daunorubicin, 
CPT-11, rhodamine, 
glucoronate conjugates 
Multidrug resistance 
phenotype 
Unknown 
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Table 3 - Expression of multidrug resistant ABC transporters in cancer cells (33) 
High expression (+++); moderate expression (++); low expression (+); very low to no expression (±). 
Cell type 
   
Transporter 
    
 
ABCB1 
(MDR1) 
ABCC1 
(MRP1) 
ABCC2 
(MRP2) 
ABCC3 
(MRP3) 
ABCC4 
(MRP4) 
ABCC5 
(MRP5) 
ABCC10 
(MRP7) 
 
ABCCG2 
(BCRP) 
Breast 
   BT-549 
  HS578T 
  MCF7 
  NCI_ADR_RES 
 
      + 
      ++ 
      ± 
      +++ 
 
      +   
      +    
      +    
      ++ 
 
      ++   
      +   
      ±   
      ± 
 
      +   
      +++   
      ±    
      ±  
 
      +++   
      +    
      ±   
      ±       
 
     ++   
     +++   
     +++   
     ++ 
 
     ++   
     +++   
     ++   
    +++ 
 
      +   
      ++   
      +++   
      ± 
Colon 
   COLO205 
  HCC-2998 
  HCT-116 
  HCT-15  
   HT29 
 
       ± 
       ± 
       ± 
       +++ 
       ± 
 
      ++ 
      +      
      ++ 
      +     
      ++   
 
      +++   
      +++   
      +++    
      ±    
      ± 
 
      +++   
      +++ 
      ++    
      ±    
      +++ 
 
      +   
      ±   
      ++  
      + 
      ++ 
 
      +   
      +++  
      ++   
      ++   
      ± 
 
      ±   
      ±    
      +++   
      +   
      ++ 
 
     +++   
     +++   
     +   
     ±   
     +++ 
Lung 
   A549-ATCC 
  NCI-H226 
  NCI-H23 
  NCI-H322M 
  NCI-H460 
  NCI-H522 
 
       ± 
       ± 
       ± 
       ± 
    +++ 
       + 
 
      + 
     ++ 
     ++ 
    +++ 
     ++ 
     ++ 
 
      ++ 
      ++ 
     +++ 
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1.4.2.Glutathione system 
 
The tripeptide, γ-L-glutamyl-L-cysteinyl-glycine known as glutathione (GSH), is the most 
important molecular low weight antioxidant synthesized in animal cells and also in most 
plants and bacteria. It is synthesized by the sequential addition of cysteine to glutamate 
followed by the addition of glycine. Glutathione functions in metabolism, transport and 
cellular protection.  The sulfhydryl group (-SH) of the cysteine is utilized in the reduction 
of the disulfide linkages of proteins and other molecules (protein repair), in the synthesis 
of deoxyribonulceotide precursors of DNA, and in the protection of cells against the 
effects of free radicals and of reactive oxygen intermediates (peroxides, superoxides, 
hydroxyl radicals) that are formed in metabolism. However, glutathione has a role in the 
inactivation of a number of drugs and in the metabolic processing of certain endogenous 
compounds, such as estrogens, prostaglandins and leukotriens. It is also a coenzyme for 
several enzymes. Cellular GSH levels are often altered in many disease states including 
cancer (33, 38, 39). 
        
1.4.2.1. Glutathione and detoxification reactions 
The cell utilizes GSH in a number of detoxification pathways. The elimination of many 
xenobiotics (foreign organic compounds not produced in metabolism) or electrophiles 
produced through the action of cytochrome P450-linked oxidases (organic halides, fatty 
acid peroxides derived from lipid peroxidation, and products derived from radiation-
damaged DNA) can be accomplished through conjugation with GSH. Conjugation to 
GSH can occur spontaneously in some instances but it is typically catalysed by one or 
more members of several different families of GSH S-transferases (GSTs). Conjugation 
reactions usually render electrophilic intermediates of exogenous and endogenous origin 
(denoted RX in the picture) less reactive and, in most cases, reduce or eliminate their 
pharmacological and/or toxic actions. These conjugated organic anions must be exported 
from cells. Their secretion is followed by cleavage of the γ-glutamil and glycyl residues 
and then acetylation by acetyl-CoA to give mercapturic acid. This more soluble, less 
toxic derivative of the original compound can be excreted in the urine or feces (38, 40).  
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        It has been established that the active cellular efflux of GSH conjugates and other 
conjugated metabolites is mediated primarily by a subset of proteins belonging to the 
ATP-binding cassette (ABC) superfamily of transport proteins. Several members of the 
ABC subfamily C (ABCC/MRP) mediate the cellular efflux of GSH conjugates and GSH 
itself, at least in vitro. Knowledge of the molecular mechanisms and physiological 
functions of MRP1 that are related to GSH and GSH conjugate transport is the most 
advanced for all of the MRP-related proteins. MDR1 has not been shown to transport 
GSH or GSH S-conjugates, but its expression appears to be modulated by intracellular 
levels of GSH (41). 
        The first and still best-caracterized physiological GSH conjugate transported by 
MRP1 in vitro and  in vivo is the cysteinyl leukotriene (LT)C4 –an important mediator of 
inflammation. Other endogenous metabolites transported by MRP1 include GSH 
conjugates of prostaglandin (PG)A2 and 4-hydroxynonenal (an α,β-unsaturated 
hydroxyalkenal which is produced by lipid peroxidation in cells, and has been linked to 
the pathology of several diseases such as Alzheimer's disease, cataract, atherosclerosis, 
and cancer (42)). Xenobiotic substrates of MRP1 range from GSH conjugates of known 
carcinogens such as aflatoxin B1 and 4-nitroquinoline 1-oxide to GSH conjugates of 
therapeutics and antineoplastic agents (acetaminophen, ethacrynic acid, doxorubicin, 
daunorubicin, cycolophosphamide, melphalan, cholambucil, thiotepa), herbicides and 
pesticides (40, 43). The ability of MRP1 to transport GSH conjugates led to the proposal 
that the former confers resistance to certain drugs (doxorubicin, vincristine, vinblastine) 
by exporting their conjugated metabolites. The requirement for GSH explains why the 
                                                                        
                    γ-Glu         X¯                   γ-Glu    Gly+Glu                      Ac-S-CoA 
 
RX + HS    Cys                     R    S    Cys                   R     S    CH2                   R     S     CH2  
                     
                    Gly                                  Gly                    H     C     NH3     CoA-SH   H     C   NH-Ac                    
                                                                                              
                                                                                              COO¯                              COO¯ 
            
 
      Glutathione                                                        R-cysteine conjugate                      Mercapturic                      
                                                                                                                                        acid                                                                                                        
                                                                                              
                                                                                             
+ 
 24 
efflux of some drugs by MRP1 is inhibited (and drug resistance reversed) when 
intracellular GSH levels are depleted by exposure of cells to buthionine sulfoxamine (44). 
        Observations in recent years suggest that the function of MRP1 is not limited to the 
extrusion of GS-X conjugates, but that MRP1 transports GSH itself, thus playing an 
important role in modulation of GSH levels, both intracellularly and extracellularly. 
Elevated GSH levels have been observed in tissues of MRP1 knockout (-/-) mice (45). 
MRP1 also transports glutathione disulfide (GSSG) with a relative high affinity. 
Furthermore, MRP1-mediated GSSG efflux occurs during oxidative stress in several cell 
types, including astrocytes, endothelial cells and probably erythrocytes (46, 47, 48, 49). 
         MRP1-mediated GSH export from cells can be greatly enhanced by several 
different xenobiotics. The calcium channel blocker verapamil was reported to stimulate 
GSH transport on MRP1 without itself being transported (50, 51). It was also found that 
some flavonoids have the same effect on MRP1. The dietary flavone apigenin is one of 
the most effective bioflavonoids and stimulates GSH transport by increasing the uptake 
affinity of MRP1 >50-fold for the tripeptide, but it is unknown how this is done (52, 53) 
(Fig. 7). 
 
 
         
       
 
        
 
 
 
 
 
 
 
 
 
Figure 7. MRP-mediated GSH extrusion from cancer cells may potentiate cancer 
therapies that have pro-oxidant effects, including alkylating agents and radiation 
therapy, by at least three separate mechanisms: (1) limiting the availability of cellular 
GSH needed for metabolizing and transporting some alkylating agents out of the cell. 
Direct effects of some flavonoids on mitochondria function cannot be discarded 
(discontinued arrow); (2) active transport of intracellular GSH, which lowers the cell’s 
antioxidant capacity to defend against alkylating agents and radiotherapy; and (3) 
sensitizing the mitochondria to treatments that induce the over-production of ROS in 
this organelle, making it easier for the cell to undergo apoptosis or necrosis. (taken from 
Leitner HM. (33)). 
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1.4.2.2. Glutathione and redox state modulation 
 
GSH is a major determinant of tissue redox status, which is determined by the ratio of 
reduced to oxidized glutathione (GSH:GSSG). Maintaining optimal GSH:GSSG ratios in 
the cell is critical to survival, hence, tight regulation of the system is imperative. A 
deficiency of GSH puts the cell at risk for oxidative damage. It is not surprising that an 
imbalance of GSH is observed in a wide range of pathologies, including cancer, 
neurodegenerative disorders, cystic fibrosis, HIV and aging. One mechanism that cancer 
cells use for adapting to oxidative stress is by elevating their intracellular concentration 
of GSH. 
         GSH plays a major role in removal of many reactive species. Superoxide (O2·¯ ), 
hydrogen peroxide (H2O2) and hydroxyl radical (OH·) are incompletely reduced 
oxygen species more reactive that O2 and are referred to collectively as reactive oxygen 
species (ROS). ROS are generated as byproducts of the normal metabolism of oxygen 
(normal cellular metabolism produces ROS in surprisingly large amounts) and are 
capable of reacting with and damaging DNA, proteins, and lipids. They also serve as very 
important signaling molecules regulating numerous physiological and pathological 
pathways. Mounting evidence suggests ROS plays a key role in tumorigenesis. ROS 
causes DNA damage, promotes cell proliferation and survival and activates several 
tumor-promoting signaling pathways such as NFκB and AKT pathways. On the other 
hand, intracellular ROS burst causes cell cycle arrest and triggers apoptosis. Especially, 
ROS levels are increased in cells that are exposed to various environmental stress or 
xenobiotics, including anticancer drugs, leading to activation of pro-apoptotic signaling 
molecules, such as JNK (54, 55). In addition to serving as a trigger of apoptosis, ROS are 
also formed in cells during the process of apoptosis and appear to be essential for the 
execution of cell death.  ROS level is relatively high in oncogenically transformed cells, 
as compared to the non-transformed cells (Fig. 8). This elevated level is thought to be 
essential for stimulating cell growth and sustaining high metabolism rate in transformed 
cells. Thus, under optimal growth conditions, elevated ROS levels confer a growth 
advantage to tumor cells by facilitating mitogenic signaling through activation of several 
stress kinase pathways (56). 
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The earth had an anaerobic atmosphere for its first billion years, and oxygen was 
intensely toxic to all life forms existing at that time. With the evolution of oxygen in our 
atmosphere, life forms developed both enzymatic and nonenzymatic defenses against 
oxidative stress. These mobilizing and scavenging systems to remove ROS are 
functionally critical and tightly controlled in the cell. Glutathione peroxidase in concert 
with catalase and superoxide dismutase (SOD) functions to protect cells from damage 
Figure 8 . A model to illustrate cell proliferation and cell death modulated by ROS level 
in non-transformed cells and transformed cells. Transformed cells have a higher basal 
level of ROS  than non-transformed cells. Slight increase of ROS accelerates cell 
proliferation. However, further increase of ROS lead to cell cycle arrest and apoptosis. A 
higher basal level of ROS renders the transformed cells more sensitive to further ROS 
production, resulting in a lethal ROS accumulation (readapted from Wu XJ. et al. (57)). 
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due to ROS. Glutathione peroxidase detoxifies peroxides with GSH acting as an electron 
donor in the reduction reaction, producing GSSG as an end product:  
 
                                  2GSH  +  H2O2                            GSSG  +  2H2O 
 
        The reduction of GSSG is catalyzed by GSH reductase in a process that requires 
NAPDH. It helps keep the ration of GSH to GSSG very high, about 100:1. Glutathione 
reductase is a member of the flavoprotein disulfide oxidoreductase  family and exists as a 
dimmer (58). Under conditions of oxidative stress, GR is regulated at the level of 
transcription as well as by posttranslational modifications. Alterations in glutathione 
reductase and activity have been implicated in cancer and aging (58, 59). 
        Growing data suggests that cancer cells are under increased oxidative stress 
compared to normal cells. Such evidence includes (a) enhanced ROS generation in cancer 
cells, (b) increased accumulation of ROS-mediated reaction products in cancer cells and 
their detection in the plasma and urine, (c) over-expression of antioxidant enzymes in 
response to oxidative stress in cancer cells (60). Hence, neoplastic cells may be more 
vulnerable to oxidant stress because they function with a heightened basal level of ROS-
mediated signaling which is required for the increased rate of growth. In light of this, a 
strategy could be developed to selectively kill transformed cells but not untransformed 
cells by the addition of an agent that increases ROS generation, or that decreases ROS 
scavenging capacity, thus pushing a tumor cell beyond the breaking point in terms of 
lipid peroxidation, DNA damage, and protein oxidation. Some attempts to target the 
antioxidant defenses of cancer cells involved the use of inhibitors to block GSH synthesis 
or glutathione reductase. BCNU (carmustine) is an anti-cancer drug that is an alkylating 
agent and an inhibitor of glutathione reductase (61). Buthionine sulfoxamine (BSO) is an 
example of an inhibitor of cellular GSH synthesis that has been studied in combination 
with ionizing radiation (62) and is currently in phase II clinical trials in combination with 
melphalan. Certain natural products have also shown ability to modulate cellular redox 
status targeting ROS. Β-phenylethyl isothiocyanate (PEITC), a natural compound found 
in consumable cruciferous vegetables with chemopreventive activity increased oxidant 
stress in transformed cells, possibly by generating ROS, but also by depleting cellular 
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levels of reduced glutathione (GSH), and by inhibiting the activity of glutathione 
peroxidase (63). 
       To the extent that ROS toxicity induced by certain chemotherapeutic agents can be 
an effective means of selectively eradicating malignant cells, it is useful to consider the 
most effective way to exploit this strategy. However, caution should be exercised in using 
ROS-generating agents, since ROS play important roles in toxic side effects such as 
cisplatin-induced nephrotoxicity, ototoxicity, and chemo-radiotherapy associated lung 
damage.   
 
 
1.4.3. Defective apoptotic pathway 
 
Altered functions of genes involved in apoptosis, such as p53, Bcl-2 and various others 
has been shown to result in malignant transformation in experimental models and are 
known today to play an important role in tumorigenesis in man. In fact, impaired ability 
to die via apoptosis (the programmed cell death) seems to be a characteristic of most 
human tumors and thus might be a significant factor in clinical multidrug resistance (64).  
        The p53 gene, first described in 1979, was the first tumor-suppressor gene to be 
identified. It encodes the p53 protein and integrates numerous signals that control cell life 
and death. The p53 network is normally ‘off’. It is activated only when cells are stressed 
or damaged. The p53 protein shuts down the multiplication of stressed cells (damage to 
chromosomal DNA incurred by ionizing irradiation and exposure to ultraviolet light, 
activation of oncogenic signaling, hypoxia or nucleotide depletion), inhibiting progress 
through the cell cycle, but in many cases it even causes apoptosis (Fig.`9). The p53 exerts 
its role in cell cycle inhibition by stimulating the expression of p21, an inhibitor of 
cyclin-dependent kinases (CDKs) and subsequently both the G1-to-S and the G2-to-
mitosis transitions (65). The p53 role in apoptosis, however, includes the Bcl-2 protein 
family and its apoptosis-inducing members (such as the Bax protein). Transcription of the 
Bax gene in some human cells is directly activated by p53-binding sites in the regulatory 
region of the gene (66). The p53 protein therefore provides a critical brake on tumor 
development, explaining why is so often mutated (and thereby inactivated) in cancers. 
Indeed, the p53 protein does not function correctly in most human cancers and can 
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contribute not only to aggressive tumor behaviour but also to therapeutic resistance (65, 
67). 
 
                        Figure 9.  Tumor growth suppression and therapeutic sensitivity is controlled  
                           by the p53 gene through activation of cell cycle arrest, DNA repair, inhibition  
                           of angiogenesis and apoptosis in response to stress. 
 
 
 
A body of evidence supporting the importance of p53 in therapeutic response has come 
from studies of p53 wild-type versus p53-null normal cells and lymphomas (68, 69).. It 
has been shown that wildtype p53-expressing cells were much more likely to undergo 
apoptosis following exposure to cytotoxic chemotherapeutic agents or ionizing radiation. 
On the other hand, it has been revealed that p53-deficient lymphoma cells are slow to 
respond to cytotoxic therapy and invariably relapse and confer a poor survival to the 
mice. A role for the Bcl-2 protein family and its antiapoptotic members (Bcl-2 and Bcl-
xL) in impaired response to chemotherapeutics has also been reported. Interestingly, cells 
that carry wild-type p53 but also express the antiapoptotic protein Bcl-2 are also less 
responsive to chemotherapy (69). A strong correlation between high expression of Bcl-2 
and poor prognosis in a number of neoplasms has been demonstrated. Forced expression 
of Bcl-2 in tissue cultures cells has been observed to prevent apoptosis due to several 
hundred different treatments, including the majority of agents used as cancer 
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chemotherapy (70). Moreover, alterations of another member of antiapoptotic Bcl-2 
family, Bcl-xL, might contribute to drug resistance as well. High Bcl-xL levels have been 
shown to correlate with a poorer prognosis in cancer patients (71, 72). 
 
 
Despite a better understanding of the disease and the advent modern technology and 
rationally targeted drugs, the incidence of cancer has not improved. It is still one of the 
leading causes of death throughout the world, coming right after diseases of the 
circulatory system. Moreover, in some European countries (France, Spain, United 
Kingdom, Ireland), cancer mortality rates are almost equal or even higher than those of 
cardiovascular diseases (73). This “slow-changing” statistics warrants new therapeutic 
strategies. 
        The relatively low sensitivity of colon cancer cell types to existing chemotherapy 
and a narrow therapeutic index of the drugs currently used to treat the disease, may 
require the generation of sensitizing strategies or appropriate drug combinations to 
synergize anti-tumor effects without increasing damage to normal tissues.   
        Around 2500 years ago Hippocrates first espoused the "food as medicine" 
philosophy, which fell into obscurity by the 19th century. In the past decades, numerous 
epidemiological studies have shown that regular consumption of fruits and vegetables as 
well as whole grains is strongly associated with reduced risk of developing chronic 
diseases, especially cancer and cardiovascular diseases. Therefore, it was reasonable for 
scientist to identify the bioactive compounds responsible and hope to find the “magic 
bullet” that could be used for prevention and therapy of cancers. Natural products derived 
from plants have recently received much attention as potential chemopreventive and 
chemotherapeutic agents. Among them great attention has been given to natural products 
with established antioxidant activities and less toxicity in normal cells, such as tea 
polyphenols and resveratrol. These substances appear very promising for cancer 
prevention and treatment in preclinical models and clinical trials.  
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1.5. Phytochemicals  
Phytochemicals are bioactive nonnutrient compounds found in plants and are generally 
involved in defense against ultraviolet radiation or aggression by pathogens such as 
bacteria, viruses, and fungi. Eating large amounts of brightly colored fruits and 
vegetables (yellow, orange, red, green, white, blue, purple), whole grains/cereals, and 
beans containing phytochemicals may decrease the risk of developing certain cancers as 
well as diabetes, hypertension, and heart disease. The action of phytochemicals varies by 
color and type of the food. They may act as antioxidants or nutrient protectors, or prevent 
carcinogens from forming. It is estimated that more than 5000 individual phytochemicals 
have been identified in fruits, vegetables, and grains, but a large percentage still remain 
unknown.  
      Phytochemicals can be classified as carotenoids, phenolics, alkaloids, nitrogen-
containing compounds, and organosulfur compounds (74).  
 
 
 
 
Flavonoids 
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The most studied of the phytochemicals are the phenolics and carotenoids. 
Phenolics are compounds possessing one or more aromatic rings with one or more 
hydroxyl groups and generally are categorized as phenolic acids, flavonoids, stilbenes, 
coumarins, and tannins. Phenolics are the products of secondary metabolism in plants, 
providing essential functions in the reproduction and the growth of the plants; acting as 
defense mechanisms against pathogens, parasites, and predators, as well as contributing 
to the color of plants. In addition to their roles in plants, phenolic compounds in our diet 
may provide health benefits associated with reduced risk of chronic diseases. Among the 
11 common fruits consumed in the western world, cranberry has the highest total 
phenolic content, followed by apple, red grape, strawberry, pineapple, banana, peach, 
lemon, orange, pear, grapefruit (75). Among the 10 common vegetables, broccoli 
possesses the highest total phenolic content, followed by spinach, yellow onion, red 
peper, carrot, cabbage, potato, lettuce, celery and cucumber (76). It is estimated that 
flavonoids account for approximately two thirds of the phenolics in our diet and the 
remaining on third are from phenolic acids. 
 
Flavonoids are a group of phenolic compounds found in fruit, vegetables, grains, bark, 
roots, stems, flowers, tea, and wine, that all were known for their beneficial effects on 
health long before flavonoids were isolated as the effective compounds. More than 4000 
varieties of flavonoids have been identified, many of which are responsible for the 
attractive colors of flowers, fruit, and leaves (77). Research on flavonoids received an 
added impulse with the discovery of French paradox, i.e., the low cardiovascular 
mortality rate observed in Mediterranean populations despite a high intake of saturated 
fat, which was thought to be attributable to high wine consumption (78). The flavonoids 
in red wine were found to be responsible, at least in part, for this effect (79). 
        Flavonoids commonly have a generic structure consisting of two aromatic rings (A 
and B rings) linked by three carbons that are usually in an oxygenated heterocycle ring, 
or C ring (Fig. 10). 
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                                                     Figure 10.  The generic structure of flavonoids 
 
 
        The biological activities of flavonoids and their metabolites depend on their 
chemical structure and relative orientation of various moieties on the molecule. The basic 
structure of the flavonoid nucleus allows for a multitude of substitution patterns in the A, 
B, and C rings, resulting in various subgroups. The flavonoids are divided into classes 
according to the chemistry of the C-ring (the variations in the number and distribution of 
the phenolic hydroxyl groups across the molecules, and their distribution): 
anthocyanidins, flavanols (catechins), flavones, flavonols, flavanones, and 
isoflavonoids.  
        The structures of flavonoids differ greatly within the major classifications and 
substitutions include glycosylation, hydrogenation, hydroxylation, malonylation, 
methylation, and sulfation. The pattern of conjugation, glycosylation, or methylation can 
be very complex, can modify the hydrophilicity of the molecule and its biological 
properties, and markedly increase the molecular weight of the flavonoid. Flavonoid 
molecules not attached to sugar moieties are referred to as the aglycone form, whereas 
flavonoid molecules with sugar moieties are called flavonoid glycosides (80). 
        Except for catechins, flavonoids do not occur in plants as aglycones; the most 
frequently occurring forms are the glycoside derivatives in plants (81). Glycosylation 
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increases the polarity of the flavonoid molecule, which is necessary for storage in plant 
cell vacuoles.  
       When glycosides are formed, the preferred glycosylation site on the flavonoid 
molecule is the C-3 position and, less frequently, the C-7 position (82). D-glucose is the 
most usual sugar residue. Other carbohydrate substitutions include arabinose, galactose, 
glucorhamnose, lignin, L-rhamnose, and xylose.  
        Flavonoids exert a wide range of biochemical and pharmacological properties, with 
one of the most investigated being their cancer preventive activities.  The cancer 
protective effects of flavonoids have been attributed to a wide variety of mechanisms, 
including free radical scavenging, modifying enzymes that activate or detoxify 
carcinogens, and inhibiting the induction of the transcription factor activator protein-1 
(AP-1) activity by tumor promoters. (83, 84).  Moreover, accumulating evidence suggest 
that flavonoids might exert modulatory effects in cells through selective actions at 
different components of a number of protein kinase and lipid kinase signaling cascades 
such as phosphoinositide 3-kinase (PI 3-kinase), Akt/PKB, tyrosine kinases, protein 
kinase C (PKC), and MAP kinases (85). Inhibitory or stimulatory actions at these 
pathways are likely to profoundly affect cellular function by altering the phosphorylation 
state of target molecules and/or by modulating gene expression. The selective inhibitory 
actions at these  
kinase cascades may be beneficial in cancer, proliferative diseases, inflammation and 
neurodegeneration.  In the past decade, numerous studies demonstrated the ability of 
flavonoids to inhibit invasive behavior of cancer cells, which allows them to be 
considered as potential candidates in adjuvant or combination therapy for the prevention 
and treatment of cancer metastasis. Some flavonoids were shown to inhibit P-gp-
mediated drug efflux and potentiate doxorubicin cytotoxicity in P-gp-positive cells (86). 
They can also induce tumor cell apoptosis by inhibiting DNA topoisomease II and p53 
downregulation (87). Interestingly, one of the possible mechanisms suggested for their 
chemotherapeutic action was their ability to increase cellular ROS levels. Although 
flavonoids are generally viewed as antioxidants, they can also generate ROS depending 
on their structure and molecular environment (88). Indeed, the pro-oxidant action of 
plant-derived phenolics rather than their antioxidant action may be an important  
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mechanism for their anticancer and apoptosis-inducing properties, as ROS can mediate 
apoptotic DNA fragmentation. Moreover, a number of flavonoids may exert direct and 
indirect prooxidant effects by inhibiting the mitochondrial respiratory chain complexes I 
and II and by inducing GSH depletion through MRP1 activation (89). 
         Although the most studied group of flavonoids are the flavonols, anthocyanidins 
probably deserve the most attention, as their daily intake in the human diet is remarkable, 
estimated at 180-215mg/day in the western world (90), which is much higher than the 
total intake estimated for other flavonoids (23mg/day). 
 
 
1.5.1. Anthocyanins 
  
Next to chlorophyll, anthocyanins (Greek antos, flower and kyanos, blue) are the most 
important group of plant pigments visible to the human eye. They are dissolved in the 
vacuolar sap of the epidermal tissues of flowers, fruit, and vegetables, to which they 
impart a red, blue, orange or purple color (91, Table 4). Anthocyanins play a definite role 
in attracting animals in pollination and seed dispersal. They may also have a role in the 
mechanism of plant resistance to insect attack. In contrast to the other flavonoids, 
anthocyanins carry a positive charge in the central ring structure and are thus cations. 
They are water-soluble and, depending upon pH and the presence of chelating metal ions, 
occur in different chemical conformations with varying colors or color intensities (92) 
        In the human diet, anthocyanins are found in red wine, certain varieties of cereals, 
and certain leafy and root vegetabeles (red cabbage, purple sweet potatoes, onions, 
radished, beans), but they are most abundant in fruit (berries, cherries, red grapes, plums). 
Food contents are generally proportional to color intensity and reach values up to 2-4g/kg 
fresh weight in blackcurrants or blackberries. These values increase as the fruit ripens. 
Anthocyanins are found mainly in the skin, except for certain types of red fruit, in which 
they also occur in the flesh (cherries and strawberries). Wine contains 200-350 mg 
anthocyanins/L, and these anthocyanins are transformed into various complex structures 
as the wine ages (93). 
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Table 4. Color and distribution of major anthocyanidins in some common fruits and 
vegetables (readapted from Wang H. et al. (94)).  
 
compound     color                 fruits and vegetables 
delphinidin bluish red concord grape, blueberry, bilberry, black currant 
cyanidin orange red strawberry, blackberry, cherry, red cabbage, bilberry, 
cranberry, elderberry, black currant, grape, plum, 
raspberry 
pelargonidin orange strawberry, corn 
malvidin bluish red grape, blueberry, bilberry 
peonidin  red cherry, cranberry, sweet potatoes, plum 
                  
 
        In plants, anthocyans are present exclusively in a glycosylated form, which is 
resistant to light, pH, and oxidation conditions that are likely to degrade them. The 
number and nature of the different attached sugar moieties are responsible for the high 
number of anthocyanins, more than 500 compounds (95). The aglycon (named 
anthocyanidin) is a diphenilpropane-based polyphenolic ring structure, and is limited to 
a few structure variants including delpinidin, cyanidin, pelargonidin, malvidin and 
petunidin (Fig. 11). 
 
                                     
                                      GLYCOSIDE = AGLYCONE  +  GLYCONE 
 
  
                                      anthocyanin       anthocyanidin           sugar 
 
        The most prevalent sugars substituted on the aglycon in nature are glucose, 
rhamnose, xylose, galactose, arabinose, and fructose, which are usually conjugated to the 
anthocyanidin molecule via the C3 hydroxyl group in ring C or attached at the 5, 7-
position on the A-ring. Glycosylation at the 3’-, 4’-, 5’-positions of the B-ring, although 
very rare, has also been observed (96). 
. 
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              Figure 11. Chemical structure of anthocyanidins (taken from Wang LS. et al. ( 97)). 
 
                                                          
 
 
        There is some controversy over the relative contributions of glycosylated 
anthocyanins versus aglycones in terms of bioavailability and bioactive potential (98). It 
was for a long time believed that only aglycones were adsorbed by intestinal cells (being 
capable of passing through the gut wall) and brought into the blood stream because of the 
absence of a bound sugar residue. Since no specific enzymes were known to selectively 
hydrolyze these glycosidic bonds, it was presumed that anthocyanins were poorly 
absorbed. However, this conviction has now been changed since in vivo absorption and 
metabolism of anthocyanin glycosides has been demonstrated by numerous studies- 
together with anthocyanidins, also anthocyanins have been detected in human and/or rat 
plasma and urine after oral administration of different glycoside forms (99, 100). The 
nature of the sugar conjugate and the aglycone are important determinants of anthocyanin 
absorption and excretion in both humans and rats by results of numerous studies. 
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        Anthocyanins were incorporated into the human diet many centuries ago. They were 
components of the traditional herbal medicines used by North American Indians, the 
Europeans, and the Chinese, and were habitually derived from dried leaves, fruits 
(berries), storage roots, or seeds. Anthocyanin-rich mixtures and extracts (though not 
purified compounds) have been used historically to treat conditions as diverse as 
hypertension, pyrexia, liver disorders, dysentery and diarrhoea, urinary problems 
including kidney stones and urinary tract infections, and the common cold. They have 
even been purported to yield improvements to vision and blood circulation.  
        An enhanced intake of anthocyanins is now increasing because extracts with higher 
anthocyanidin contents from bilberry and elderberry are commercially available. Recent 
studies using purified anthocyanins or anthocyanin-rich extracts on in vitro experimental 
systems have confirmed the potential potency of these pigments. Along with other 
phenolics, anthocyanins are potent scavengers of free radicals. These natural compounds 
can react with reactive oxygen species (ROS) and thus interrupt the propagation of new 
free radical species (94, 101). This ability has been associated with their protective role 
from different diseases. Epidemiological investigations have indicated that moderate 
consumption of anthocyanins through the intake of products such as red wine or bilberry 
extract is associated with a lower risk of coronary heart disease (102, 103). Demonstrable 
benefits also include protection against liver injuries (104); significant reduction of blood 
pressure; strong anti-inflammatory and antimicrobial activities (105). Among a broad 
spectrum of their biological activities, extremely important are their scavenging effects 
on activated carcinogens and mutagens and a subsequent cancer protective effect. Animal 
experiments showed that oral intake of anthocyanins from purple sweet potato and red 
cabbage suppressed rat colon carcinogenesis induced by 1,2-dimethlhydrazine and 2-
amino-1-methyl-6-phenylimidazo-[4,5-b] pyridine (106). Along with their 
chemopreventive effects, anthocyanins have also demonstrated a role in cell-cycle 
regulation. They have been shown to interrupt the cell cycle at G1 or G2/M phase and to 
have a pro-apoptotic effect in different tumour cell lines (107, 108, 109). These studies 
suggest that anthocyanins may also play a role in suppression of proliferation of human 
cancer cells and may have potential as agents for cancer treatment as well. All of these 
activites are thought to be related to the antioxidant properties of anthocyanins. However, 
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some recent studies point out that they can also behave as pro-oxidants (110). 
Interestingly, it has been indicated that a natural antioxidative product, cyanidin 3-
rutinoside, may exhibit pro-oxidant activities selectively in leukemic cells (90). This 
effect could be further exploited in the development of antitumor agents that have a low 
toxicity toward normal cells.  
        As far as molecular mechanisms behind anticarcinogenic, anti-inflammatory and 
antitumor progression effects of anthocyanidins are concerned, different hypothesis have 
been tested. 
 
       1.5.1.1. Anticarcinogenesis through targeting MAPK pathway and AP-1 factor 
 
AP-1 is a transcription factor and has been shown to play a critical role in promoting 
carcinogenesis (111). In mouse epidermal cell line JB6, tumor promoters such as 12-O-
tetradeconoylphorbol-13-acetate (TPA), epidermal growth factor (EGF), and tumor 
necrosis factor (TNF) alpha can induce AP-1 activity and neoplastic transformation by 
activating MAPK including ERK, JNK, or p38 kinase (112). Delphinidin, cyanidin, and 
petunidin have been shown to inhibit TPA-induced AP-1 transcriptional activity and cell 
transformation in JB6 cells. The ortho-dihydroxyphenyl structure on the B-ring seems to 
be essential for this inhibitory action (113). The results from signal transduction analysis 
indicated that delphinidin blocked ERK phosphorylation at early times and JNK 
phosphorylation at later times, but not p38 phosporilation at any time, suggesting that the 
inhibition of TPA-induced AP-1 activity and cell transformation by delphinidin involves 
blockage of ERK and JNK signaling cascade (Fig. 12). Furthermore, a greater inhibition 
was observed in combinations of superoxide dismutase (SOD) with anthocyanidins. This 
leads to the conclusion that the inhibitory effects of anthocyanidins on AP-1 activation 
and cell transformation would be due in part to their potent scavenging activity for 
superoxide radicals and in part to MAPK blockage (95).  
        
       1.5.1.2. Anti-inflammation through targeting NF-κB pathway and COX-2 gene 
 
Inflammation has been shown to play a role in the promotion of some types of cancer in 
animals and humans (114). Abnormal up-regulation of two inflammatory proteins, nuclar 
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factor-kappa B (NF-κB) and cyclooxygenase-2 (COX-2), is a common occurance in 
many cancers. Inhibitors of these proteins, such as some antioxidants, usually exhibit 
significant chemopreventive potential (115).  Through their ability to inhibit the mRNA 
and/or protein expression levels of COX-2, NF-κB and various interleukins, the 
anthocyanins have exhibited anti-inflammatory effects in multiple cell types in vitro. 
(116, 117). For example, treatment of JB-6 C1 41 mouse epidermal cells with an 
anthocyanin-rich extract from black raspberries resulted in down-regulation of 
benzoapyrene diol-epoxide (BaPDE)-induced expression of NF-κB (118). Moreover, 
anthocyanian extracts from bilberry or purified delphinidin inhibited LPS-induced COX-
2 expression at protein and transcriptional levels. Delphinidin blocked LPS-induced IκB 
degradation and then suppressed NF-κB activation and COX-2 gene expression (95). This 
demonstrates that the blockage of NF-κB signaling pathway is involved in the inhibition 
of COX-2 gene expression by anthocyanins (Fig. 12). 
        
 
 
 
 
 
 
 
 
 
Figure 12.  A schematic molecular view of cancer chemoprevention by anthocyanidins. 
Anthocyanidins may contribute to cancer chemoprevention through targeting three different signal 
trandsuction pathways and downstream genes (Readapted  from Hou DX. et al. (95)). 
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       1.5.1.3. Antitumor progression through induction of apoptosis  
 
Apoptosis, or programmed cell death, plays a key role in the development and growth 
regulation of normal cells, and is often dysregulated in cancer cells. The cells that have 
undergone apoptosis have typically shown chromatin condensation and DNA 
fragmentation (119) . They are rapidly recognized by macrophages before cell lysis, and 
then can be removed without inducing inflammation (120).  Therefore, apoptosis-
inducing agents are expected to be ideal anticancer drugs. Indeed, some of the most 
effective chemopreventive agents are strong inducers of apoptosis in premalignant and 
malignant cells. Anthocyanin-rich extracts from berries and grapes, and several pure 
anthocyanins and anthocyanidins, have exhibited pro-apoptotic effects in multiple cell 
types in vitro (121, 122) They can induce apoptosis through both intrinsic 
(mitochondrial) and extrinsic (FAS) pathways, and these are dependent on upstream 
activation of JNK pathway which appeared to act cooperatively since inhibition of the 
kinase was sufficient to block apoptosis (123). Moreover, analysis indicates that the 
apoptosis induction by anthocyanidins may involve an oxidation/JNK-mediated caspase 
pathway (Fig. 12).  Anthocyanidin treatment of leukemic cells increased the levels of 
intracellular ROS, which was a sensor to activate the stress kinases (JNK, p38) and 
subsequently the pro-death Bcl-2 family proteins and the mitochondrial apoptotic 
pathway. Antioxidants, such as N-acetyl-L-cysteine (NAC) and catalase effectively 
blocked anthocyanidin-induced JNK phosphorylation, caspase 3 activation, and DNA 
fragmentaion  (90, 108). The potency of anthocyanidins to increase the levels of ROS and 
induce apoptosis was dependent on the number of hydroxyl groups at the B-ring (108) . It 
is interesting that treatment of cancer cells with anthocyanins leads to an accumulation of 
ROS and subsequent apoptosis (90) contrary to the antioxidant and protective activities 
they showed in non-transformed cells (95). But, it is not yet clear how anthocyanins 
promote oxidative stress in cancer cells.   
 
  
Most of the molecular results on biological activities of anthocyanins were from 
anthocyanidins due to the fact that anthocyanidins are easier to be prepared than 
anthocyanins. Thus, it is not yet known whether the naturally occurring anthocyanins will 
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also activate same molecular pathways. Accumulated results on structure-activity studies 
have shown that the biological activities of anthocyanins appear to increase with 
decreasing number of sugar moieties and/or with an increasing number of hydroxyl 
groups at their aglycons (97, 110).  
 
 
 
 
 
1.6 . Scope of the thesis 
 
 
The story about bioactive properties and potentials of natural sources that surround us, 
still in their mystery, inspired us to embark on a challenging project whose aim was to 
test the cytotoxic properties of anthocyanidins in human colorectal carcinoma cells. We 
wanted to see whether they are able to affect cancer cell growth and to modulate the 
cytotoxicity of certain well established anticancer drugs. We also wanted to test pro-
apoptotic properties of anthocyanidins in these cells. Furthermore, we have focused on 
their not yet completely clear role as oxidative-stress inducing agents in malignant cells 
and the possible mechanisms for this action. Finally, their ability to modulate the 
expression of ABC transporter proteins, whose over-expression confers drug resistance 
on malignant cells, was also a domain of our interest. We hope that this study can 
contribute to the global need for the development of new antitumor agents, with a higher 
therapeutic index and fewer side-effects.  
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2. Materials and methods 
 
 
2.1. Reagents   
 
Deplhinidin-, cyanidin-, malvidin-, and pelargonidin chloride were purchased from 
Extrasynthèse (Genay, France); camptothecin and doxorubicin were from Sigma-Aldrich 
(Milano, Italy). Stock solutions were prepared by dissolving the substances in either 
dimethyl sulfoxide (anthocyanidins), or sodium hydroxide (camptothecin), or distilled 
water (doxorubicin), and stored at –20°C. The final content of dimethyl sulfoxide in all 
experiments was kept under 0.2%.  
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT), 2’,7’-
dichlorofluorescin diacetate (DCFH-DA), 2,2’-azobis (2-amidinopropane) 
dihydrochloride (ABAP), glutathione reductase (GR), NADPH, GSH, and glutathione 
disulfide (GSSG) were obtained from Sigma-Aldrich (Milano, Italy).  
The following primary and secondary antibodies were used: anti-P-gp (Ab’ C219) 
(Alexis), anti-MRP1 (Ab’ A23) (Alexis), anti-BCRP (Ab’ clone BXP-21) (Sigma-
Aldrich), GAM-FITC (Sigma-Aldrich), GAR-FITC (Sigma-Aldrich). The kit used for 
RT-PCR was SV Total RNA Isolation System (Promega, U.S.A.).  
 
 
2.2. Cell lines 
 
• Caco-2 – cell line isolated from a primary human colonic tumor/adenocarcinoma; 
upon reaching confluence, the cells express characteristics of enterocytes; 
maintained in Minimum Essential Medium Eagle-MEME (Sigma-Aldrich, 
Milano, Italy) supplemented with 10% FBS, 1% penicillin-streptomycin, L-
glutamine, and sodium pyruvate (1mM final concentration) 
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• LoVo - metastatic human colorectal adenocarcinoma cell line, maintained in 
RPMI-1640 (Sigma-Aldrich, Milano, Italy) supplemented with 10% FBS, 1% 
penicillin-streptomycin, and L-glutamine 
•  LoVo ADR - metastatic human colorectal adenocarcinoma cell line, doxorubicin 
resistant, maintained in RPMI-1640 supplemented with 10% FBS, 1% penicillin-
streptomycin, L-glutamine and doxorubicin (200ng/mL). 7 days before each 
experiment doxorubicin was removed from the medium.  
 
 
 
2.3. MTT assay for cellular viability 
  
IC50 values of anticancer agents and natural products were determined by means of the 3-
(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay, based on 
mitochondrial reduction of the tetrazolium compound MTT to yield a soluble formazan 
product that can be assayed colorimetrically. Exponentially growing cells were seeded in 
a 96-well plate in complete culture medium and treated with designed concentrations of 
camptothecin 0.001-50µM and/or anthocyanidins 0.78-100µM,  for 68h at 37ºC in a 
humidified chamber. The total medium volume in each well was 200µL. Each 
concentration of each substance was repeated in 10 wells. There were 30 control wells. 
For anthocyanidins one of the contol lines contained 0.2% of DMSO (v/v). After 
incubation for specified times at 37ºC, MTT reagent (20µL, 5mg/mL in PBS) was added 
to each well and incubated for additional 4 hours. The MTT solution was removed from 
the wells by aspiration and the formazan crystals were dissolved in DMSO (200µL). 
Absorbance was recorded on a microplate reader at 540 with a reference wavelength of 
630 nm. The IC50 (concentration of a substance that inhibits 50% of cell growth) was 
defined as the drug concentration required to reduce the optical density in each test to 
50% of controls. All IC50 values were determined from three independent experiments.  
         In order to determine if the anthocyanidins are able to change the cytotoxicity of 
camptothecin, the same test was performed. The IC20 value of camptothecin (0.01µM) 
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was used and three different concentrations of delphinidin and cyanidin (10, 25 and 
50µM).  
 
 
 
2.4. Determination of apoptosis 
 
Cells were seeded at a density of 15x104/well in a six-well plate onto sterilized 
microscope glasses, left to attach for few hours after which they were treated with 
delphinidin or cyanidin (100µM) for 24h, or with camptothecin (1µM) for 12h. The 
control well contained only medium. After that it was proceeded with DAPI staining. The 
medium was aspirated and the glasses were washed with PBS (3x 2mL, 5 min each). The 
cells were fixed with 2% paraformaldehyde (diluted in PBS) and left at room temperature 
for 30min. The glasses were washed again, after which the cells were permeabilizied with 
0.2% Triton (diluted in PBS), for 15min on a shaking platform. After few new washes, 
the cells were incubated with 5µg/mL DAPI, 5-7 min in the dark at room temperature, 
and washed again. Finally, they were dehydrated with 70%, 90%, 100% ethanol (5min 
each) and the glasses were left to air dry before coverslipping. 
 
 
2.5. Cellular antioxidant activity (CAA) assay 
 
The intracellular formation of hydrogen peroxide was detected by using the method of 
Wolf et al. (124). The proposed principle is shown in Figure 13. 
        Namely, LoVo, LoVo ADR and CACO-2 cells were seeded at a density of 
1x104/well (LoVo,LoVo ADR) or 2x104/well (CACO-2) on a 96-well microplate in 
100µL of growth medium/well. The outside wells of the plate were not used. Twenty-
four hours after seeding, the growth medium was removed and the wells were washed 
with 100µL PBS. After this step, the cells were treated for 1 hour with 100µL of 
delphinidin or cyandin (25µM, 50µM, 100µM) plus 25µM DCFH-DA dissolved in 
treatment medium. After 1h, the solutions were removed by aspiration, and the cells were 
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washed with PBS. Then 600µM ABAP was applied to the cells in 100µL of HBSS, and 
the 96-well microplate was placed into a Microplate Reader, Bio-Tek Instrument at 37ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Emission at 538 nm was measured with excitation at 485 nm every 5 minutes for 1h. 
Each concentration of each substance was repeated in 6 wells. Each plate also included 6 
control and 6 blank wells: control wells contained cells treated with DCFH-DA and 
 
  Seed cells on 96-well 
24h 
Wash with PBS 
 
Treat with delphinidin/cyanidin +   
           25µM DCFH-DA  
1h 
Wash with PBS 
   Treat with 600µM ABAP 
   Read fluorescence for 60min 
      Abs=485nm; Em=538nm 
Cellular  
esterases 
 
Figure 13. Method and proposed principle of the cellular antioxidant activity (CAA) assay. Cells 
were pretreated with delphinidin or cyanidin and DCFH-DA. The anthocyanidins bound to the cell 
membrane and/or passed through the membrane to enter the cell. DCFH-DA diffused into the cell 
where cellular esterases cleaved the diacetate moiety to form the more polar DCFH, which was 
trapped within the cell. Cells were treated with ABAP, which was able to diffuse into cells. ABAP 
spontaneously decomposed to form peroxyl radicals. These peroxyl radicals attacked the cell 
memrane to produce more radicals and oxidized the intacellular DCFH to the fluorescent DCF. 
Antioxidants prevented oxidation of DCFH and membrane lipids and reduced the formation of 
DCF. Pro-oxidants, on the other hand, caused an increase in ROS accumulation which led to the 
oxidation of DCFH and increased the foramation of  the fluorescent DCF.  Readapted  from Wolf 
et al.(124). 
 
 47 
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Glutathione  
  reductase 
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oxidant (ABAP); blank wells contained cells treated with dye (DCFH-DA) and HBSS 
without oxidant. 
 
Quantification of CAA.  After blank subtraction from fluorescence readings, the area 
under the curve of fluorescence versus time was integrated to calculate the CAA value at 
each concentration of delphinidin and cyanidin as follows:  
 
                                 CAA unit = 100- ( ∫ SA/ ∫ CA ) x 100               
 
where ∫SA is the integrated area under the sample fluorescence versus time curve and 
∫CA is the integrated area from the control curve. 
 
 
 
2.6. Glutathione reductase (GR) activity 
 
Glutathione reductase (GR) is an enzyme that catalyzes the reduction of glutathione 
disulfide (GSSG) into glutathione (GSH). This reaction is dependent on NADPH as 
reducing cofactor:  
 
                                       
 
  
 
 
 
 
 
The glutathione reductase (GR) assay monitored the oxidation of NADPH consumed in 
the reduction of glutathione disulfide (GSSG) by the change in absorbance at 340nm 
(T=37ºC).  
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         The cells were seeded on a six-well plate at a density of 2.5x105/well (LoVo, LoVo 
ADR) or 5x105/well (CACO-2) and left for 3 days to reach the confluence. On the 3rd 
day, the growth medium was removed and the wells were washed with PBS. After this 
step, the cells were treated for 1 hour with 2mL of delphinidin or cyandin (25µM, 50µM, 
100µM) dissolved in treatment medium. After 1h, the solutions were removed by 
aspiration, the cells were washed with PBS, scraped with a rubber policeman, centrifuged 
and dissolved in 1mL PBS. After being counted and sonicated, the cells were proceeded 
for GR assay. The 1.5mL mixture prepared in a spectrophotometric cuvette contained: 
0.3mL of the sample; 0.1M phosphate buffer, pH 7.0; 1mM EDTA; 0.26% Triton X-100 
(“peroxide free”); 2mM GSSG and H2O to 1.5mL. This mixture was preincubated at 
5min for 37ºC and the absorbance was registered. Then NADPH (final concentration 
0.15mM) was added and the absorbance was registered for additional 15min. GR activity 
was calculated by the change in the absorbance value at 340nm. GR activity was 
expressed as nanomoles of NADPH per minute per 1x106  cells.  
 
 
2.7. Quantitative determination of glutathione and glutathione disulfide 
levels  
 
Glutathione (GSH) and glutathione disulfide (GSSG) intracellular levels were measured 
by using enzymatic recycling method described in (125). 
 
GSH assay principle: The assay is based on the reaction of GSH with the sulfhydryl 
reagent 5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB, Ellman’s reagent) that produces the 
yellow derivative 5’-thio-2-nitrobenzoic acid (TNB), which has a maximal absorbance at 
412nm, and oxidized glutathione-TNB adduct (GS-TNB). The rate of formation of TNB, 
measured at 412nm, is proportional to the concentration of GSH in the sample. The 
disulfide product (GS-TNB) is then reduced by GR in the presence of NADPH, recycling 
GSH back into the reaction. Because GR reduces the GSSG formed into 2GSH, the 
amount of glutathione measured represents the sum of reduced and oxidized glutathione 
in the sample. The rate of change in absorbance is linearly proportional to the total 
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concentration of GSH. The concentration of an unknown sample is determined by 
calculating from the linear equation or the regression curve generated from several 
standards of GSH.  
GSSG assay principle: The GSSG reductase recycling method is used for the 
determination of GSSG by monitoring NADPH spectrophotometrically. The cell extracts 
are treated with 2-vinylpyridine, which covalently reacts with GSH (but not GSSG). The 
excess 2-vinylpyridine is neutralized with triethanolamine.  
 
        The cells were treated in the same manner as for the determination of GR activity, 
after which they were harvested, counted, and centrifuged. The cells were resuspended in 
1mL of ice-cold extraction buffer (0.1%Triton-X 100 and 0.6% sulfosalicylic acid in 
0.1M potassium phosphate buffer with 5mM EDTA disodium salt, pH 7.5 (KPE)). The 
cell suspension was then sonicated and centrifuged. The supernatant was proceeded for 
glutathione determination. The absorption was read on a 96-well plate. For both the GSH 
and the GSSG assay, GSH/GSSG standards were prepared by dissolving GSH/GSSG in 
KPE. The concentration range was from 26.4-0.4nM. 
        For the GSH assay, 20µL of each standard, as well as of each sample were added to 
appropriate wells (triplicate wells for each sample). Equal volumes of DTNB 
(0.67mg/mL) and GR (13.3µL (250units/mL)/1mL) were mixed and 120µL of the mixture 
was added to each well. 30 seconds were allowed for the conversion of GSSG to GSH, 
and 60µL of NADPH was added (0.67mg/mL). The absorbance was read immediately at 
412nm in a microplate reader and the measurements were taken every 30 seconds for 2 
minutes (5 readings in total from 0-120s). The rate of TNB was calculated (change in 
absorbance/min) and the actual total GSH concentration (nM per 106 cells) in the sample 
was determined by using linear regression to calculate the values obtained from the 
standard curve.  The final GSH levels are presented as % compared to controls.  
         For the GSSG assay, the samples were incubated with 2-vinylpyridine (1:500) for 
1h at room temperature in a fume hood, after which triethanolamine (1:100) was added 
and 10 minutes were allowed for the neutralization process. The derivatized samples 
were assayed by the same method as for GSH measurement. GSSG standards (containing 
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2-vinylpyridine and triethanolamine) and sample blanks containing only 2-vinylpyridine 
and triethanolamine were also run.  
 
 
 
2.8. Doxorubicin accumulation in LoVo and LoVo ADR cells 
 
60 minutes incubation: LoVo and LoVo ADR cells were plated at 2x105/well in six- 
well plates and treated with the complete medium to reach confluence. After 4 days the 
medium was removed from the wells by aspiration, the cells were washed with PBS, and 
treated for 90 minutes as follows (each treatment was repeated in two wells):  
control: the cells were incubated in 1mL of complete medium (RPMI-1640) 
doxorubicin alone: the cells were incubated in 1mL of complete RPMI-1640 for 30 
minutes after which it was aspirated and 1mL of doxorubicin (25µM) dissolved in the 
complete medium was added and left for another 60 minutes 
verapamil+doxorubicin: the cells were preincubated with verapamil (50µM) dissolved in 
the complete medium for 30 minutes after which doxorubicin (final concentration 25 
µM) was added and treated for additional 60 minutes 
delphinidin: the cells were treated with delphinidin (50µM) for 90 minutes 
delphinidin+doxorubicin: the cells were preincubated with delphinidin (50µM) for 
30minutes after which doxorubicin (final concentration 25µM) was added and treated for 
another 60 minutes 
 
5 weeks incubation: LoVo ADR cells were seeded at 2x105 in 25cm³ flasks and treated 
with designed nontoxic concentration of delphinidin (2.5µM, 5µM, 10µM, 12µM). There 
was one flask with untreated cells that served as a control. Total volume in each flask was 
5mL. Once a week the cells were trypsinized and seeded again in new flasks at the same 
number and treated in the same way as described above. Between two trypsinizations (on 
the 4th day after every seeding) the medium was changed in all flasks and new-added 
volume was 10mL. After 5 weeks of the procedure, the cells were trypsinized, and plated 
at 2x105 in 6 well plates and treated for additional 4 days after which the 
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medium/delfinidin solution was removed from the wells by aspiration, the cells were 
washed with PBS, and treated for 90 minutes as follows (each treatment was repeated in 
two wells):  
control: the cells were incubated in 1mL of complete medium (RPMI-1640) 
doxorubicin alone: the cells were incubated in 1mL of complete RPMI-1640 for 30 
minutes after which it was aspirated and 1mL of doxorubicin (25µM) dissolved in the 
complete medium was added and left for another 60 minutes 
verapamil+doxorubicin: the cells were treated with verapamil (50µM) dissolved in the 
complete medium for 30 minutes after which doxorubicin (final concentration 25 µM) 
was added and left for additional 60 minutes 
delphinidin: the cells were incubated in 1mL of delphinidin (1µM, 2.5µM, 5µM, 10µM, 
12µM) for 90 minutes 
delphinidin+doxorubicin: the cells were treated with delphinidin (1µM, 2.5µM, 5µM, 
10µM, 12µM) for 30minutes after which doxorubicin (final concentration 25µM) was 
added and incubated for another 60 minutes 
 
Uptake was stopped by aspiration of the solutions from the wells and washing each well 
with ice-cold PBS. Cells were harvested by scraping with a rubber policeman, 
centrifuged (2400x, 7minutes at 4ºC) and washed twice. The pellet was resuspended in 
1mL of 0.3 N HCl in 50% ethanol, mixed thoroughly in a vortex mixer, and centrifuged 
at 4000x for 15 min at 4ºC. Doxorubicin content in the supernatant fraction was 
determined fluorimetrically with the method of Bachur et al. (126). 
: 
 
 
 
 
 
 
An aliquot (200µl) from each well was transferred into a 96-well plate and the 
intracellular level of doxorubicin was determined by analyzing the cell lysate on a 
fluorescence plate reader at wavelengths λexcitation 485 nm and λemission 535 nm. To 
obtain the doxorubicin standard curve for computation of doxorubicin content, 
aliquots of freshly prepared doxorubicin dissolved in 0.3 N HCl/50% ethanol were 
used, to give final concentrations ranging from 0.02µM to 10.0µM).  
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DOX concentration was expressed as µM doxorubicin/mg proteins where protein 
concentration of samples was determined by the method of Lowry et al. (127, using 
BioRad DC Protein Assay kit):  
 
 
 
                 
 
 
 
 
 
 
 
 
 
 
 
2.9. ABC transporters expression in LoVo ADR cells treated with 
delphinidin for 5 weeks 
 
2.9.1. Immunocytochemistry  
 
After 5-week treatment with 2.5, 5, 10 and 12µM delphinidin, LoVo ADR cells were 
seeded at a density of 15x104/well in a six-well plate onto sterilized microscope glasses 
and cultivated for 3 days. Then, cells were washed three times with sterile PBS and fixed 
in 2% paraformaldehyde for 30 minutes at room temperature and for additional 30 
minutes at 4ºC. The glasses were washed again with PBS (3 times for 5 minutes) and the 
cell membranes were permeabilized with 0.2% Triton X-100 for 10 minutes at 37ºC. The 
glasses were washed again with PBS and the cells were blocked with Blocking Solution 
(5% Normal Goat Serum, 4% Bovine Serum Albumine in PBS) for 1h at 37ºC 
The pellet that remained, after the supernatant had been used for determination  of            
doxorubicin content, was resuspended in lysis buffer (Tris HCl pH 7.4, 10mM; 
EDTA 100mM, NaCl 100mM, SDS 10%, H2O milliQ ) and transferred into a 96-
plate (in aliquots of 1µL and 2µL brought up to 5 µL with the lysis buffer). 
Standard curve of BSA (1mg/mL) dissolved in the lysis buffer was used for 
computation of protein content (1µL,2µL,3µL,4µL and 5µL of the protein solution 
were brought up to 5µL with the lysis buffer). 25µL of the reagent A (an alkaline 
copper tartrate solution) were added to each well and left for 5 minutes, after 
which 200µL of the reagent B (a dilute Folin reagent) were added and incubated 
for additional 5 minutes. The final protein content was determined by analyzing 
the lysates on a microplate reader at 630 nm. 
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(100µL/well). Then, cells were incubated over night at 4ºC with primary antibody diluted 
in blocking solution: 
• anti-P-gp (mouse) dil 1:50 
• anti-MRP1 (rabbit) dil 1:50  
• anti-BCRP (mouse) dil 1:3 
        Next day, the glasses were washed 3 times with PBS and cells were incubated for 1h 
at 37ºC with FITC (fluorescein isothiocyanate)-conjugated secondary antibody diluted in 
blocking solution: 
•    GAM-FITC (goat anti-mouse) dil 1:100 
• GAR-FITC (goat anti-rabbit) dil 1:200 
        After this step, the glasses were washed 3 times with PBS and 1% Tween and 
proceeded for DAPI staining: 100µL/well DAPI (diluted in PBS with 1% Tween to reach 
the final concentration of 1µg/mL) for 5 minutes at 37ºC. The glasses were washed with 
PBS and dehydrated with 50%, 80% and 100% ethanol (5 minutes each). The cover 
glasses were mounted with Glicerol-Dabco (3% Dabco, 10% 200mM Tris-HCl pH 7.4 in 
glycerol) and observed under fluorescence microscope (Leica Stereoscan 430i). 
 
          
2.9.2. RNA Extraction 
 
After 5-week treatment with 2.5, 5, 10 and 12µM delphinidin, total RNA was extracted 
from LoVo ADR cells using the SV Total RNA Isolation System kit (Promega, USA). 
~5x106 LoVo ADR cells were harvested and collected in a sterile conical tube by 
centrifugation. The cell pellet was washed with ice-cold, sterile PBS and centrifuged 
again. The supernatant was discarded. 175µL of SV RNA Lysis Buffer was added to the 
washed cells and mixed thoroughly, after which 350µL of SV RNA Dilution Buffer was 
added and incubated at 70ºC for 3 minutes. The mixture was centrifuged at 13.000 rcf for 
10 minutes and the cleared lysates were transferred to a fresh tube. 200µL 95% ethanol 
was added to the cleared lysates, mixed well, transferred to Spin Bucket Assembly 
(Promega, USA) and centrifuged at 14.000 rcf for 1 minute. After this, SV RNA Wash 
Solution (600µL) was added and centrifuged again for 1 minute. In the mean time, DNA 
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incubation mix was prepared: 40µL Yellow Core Buffer, 5µL MnCl2 0.09M, 5µL DNase 
I. 50µL of DNase mix was applied to membrane and incubated at room temperature for 
15 minutes after which the reaction was blocked by adding 200µL of SV RNA Stop 
Solution. The mixture was centrifuged for 1 minute and washed two times with SV RNA 
Wash Solution. Finally, RNA bound to membrane was eluted by centrifugation at 14.000 
rcf with 100µL of Nuclease-Free Water and stored at -20ºC until the use.  
 
 
2.9.3. Reverse transcription polymerase chain reaction (RT-PCR) 
 
Reverse transcription is the process by which RNA is transcribed into cDNA.  
        The final volume of this reaction is 20µl:  
• 10µl of RNA 
• 1µl Random primers (Promega) 
• 1µl 10mM dNTPs (Promega) 
        The reaction tube is warmed to 65ºC for 5 minutes and quickly chilled on ice. The 
rest of the reactants are added in the following manner:  
•    4µl First-Strand Buffer (Invitrogen) 
• 2µl 0.1M DTT (Dithiothreitol) (Invitrogen) 
• 1µl nuclease free water 
        The mixture is incubated at 42ºC for 2 minutes and 1µl (200 units) of SuperScript II 
(Invitrogen) –the polymerase which catalyzes the formation of complementary chains- is 
added. The reverse transcription is continued by incubating the mixture at 42ºC for 50 
minutes. The reaction is inactivated by heating at 70ºC for 15 minutes. 
        Once cDNA has been obtained from the total RNA, specific primers are used and 
polymerase chain reaction (PCR) is performed in order to determine the variations of 
ABC transporters gene expression.  
        The primers used for this PCR are the folowing: 
•    MDR1/ABCB1  (158 bp) 
- forward: 5’-3’ CCCATCATTGCAATAGCAGG 
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             - reverse : 5’-3’ TGTTCAAACTTCTGCTCCTGA 
• MRP1/ABCC1 ( 349 bp) 
- forward: 5’-3’ ATGTCACGTGGAATACCAGC 
             - reverse: 5’-3’ GAAGACTGAACTCCCTTCCT 
 
• BCRP/ABCG2 (91 bp) 
- forward: 5’-3’ AGATGGGTTTCCAAGCGTTCAT 
             - reverse: 5’-3’ CCAGTCCCAGTACGACTGTGACA 
 
        The total volume of each PCR reaction is 10 µl. The PCR mixtures are prepared in 
the following way: 
• cDNA                             1µL 
• Primer Forward              1µL 
• Primer Reverse               1µL 
• Red Taq Buffer               1µL 
• dNTPs 2.5mM                1µL 
• Red Taq polymerase       0.5µL 
(containing MgCl2)     
• nuclease free water         4.5µL  
 
        30 amplification cycles are performed and the PCR products are loaded upon a 2% 
agarose gel* using the loading TBE 1X buffer*. The electrophoretic run is performed 
on 170V for approximately 30 minutes. After electrophoresis the gel is illuminated with 
an ultraviolet lamp. The ethidium bromide stained DNA glows orange.  
 
            * 2% agarose gel: 3g agarose; 150mL TBE 1X; ethidium bromide, final concentration     
               0.5µg/mL; 
               loading TBE 1X buffer: 0.089M Tris base, 0.089M Boric acid, 0.0025M EDTA  
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        In order to see how strong is the signal and at which dilution disappears, the cDNA 
samples were diluted in the following manner: 1:10, 1:50, 1:100 and 1:200, with sterile 
nuclease free water. PCR was performed as described previously, the PCR products were 
loaded upon an agarose gel and ran electrophoretically.  
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3. Results 
 
 
 
3.1. Cytotoxicity of anthocyanidins and camptothecin in colorectal carcinoma cells  
 
Cytotoxic effects of anthocyanidins (delphinidin, cyanidin, malvidin and pelargonidin) 
and of the antineoplastic drugs camptothecin and SN-38 (an active metabolite of 
camptothecin derivative irinotecan) were determined using a 72h exposure in three types 
of colorectal carcinoma cells: CACO-2, LoVo and LoVo ADR (Table  ). Both LoVo and 
LoVo ADR cells are derived from colorectal cancer metastasis, whereas CACO-2 cells 
originate from a primary tumor sites. The cytotoxic effect is presented as IC50 value (a 
drug concentration that inhibits 50% of the cell growth) (Table 5). 
 
 
Table 5. IC50 values of delphinidin, cyanidin, and camptothecin in CACO2, LoVo and LoVo ADR cells. 
IC50 values of SN-38 and malvidin were extremely high in all cell lines, whereas pelargonidin did not show 
any cytotoxic effect. 
  
CACO-2 
 
LoVo 
  
 LoVo ADR 
 
delphinidin 
 
cyanidin 
 
 
no cytotoxic effect 
 
no cytotoxic effect 
 
37.6 ± 3.3 µM 
 
46.9 ± 1.8 µM 
 
16.4 ± 1.7 µM 
 
26.2 ± 6.2 µM 
 
camptothecin 
 
  0.13 ± 0.02 µM 
 
 
0.037 ± 0.005 µM 
 
 
 
0.2 ± 0.001 µM 
 
 
 
 
In all the selected cell lines, camptothecin induced a cytotoxic effect. LoVo cells were the 
most sensitive. The IC50 was highest in LoVo ADR cells confirming them being more 
resistant to anticancer therapy in comparison with other cell types.  
Delphindin and cyanidin showed a cytotoxic effect in both LoVo and LoVo ADR cell 
lines, whereas in CACO-2 cells no cytotoxyc effect was observed after the treatement 
with the natural products. Interestingly, in LoVo ADR cells that were less sensitive to the 
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standard chemotherapy in comparison with the LoVo cell line, the IC50 values of both 
delphinidin and cyanidin were 2 times lower than in LoVo cells, indicating a greater 
sensitivity of LoVo ADR cells to anthocyanidins used in the study.  
IC50  values of SN-38 were approximately 50-fold higher than those of camptothecin. 
Malvidin exhibited cytoxicity only at concentrations higher than 100µM, whereas 
pelargonidin did not show any cytotoxic effect even when applied in very high 
concentrations. For these reasons, these three substances were not used in the 
experiments that followed.  
 
 
3.2. Cytotoxic effects of the anthocyanidin/camptothecin combination 
 
In order to determine if anthocyanidins are able to change the cytotoxic effect of 
camptothecin, LoVo and LoVo ADR cells were exposed to the combination of 
delphindin or cyanidin and the drug. The concentration of camptothecin used in this 
experiment was calculated as the IC20 from the MTT test.  The results obtained (Fig.14, 
15) show a significant increase in the cytotoxicity (expressed as a % of dead cells in a  
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  Cytotoxyc effect of delphindin and cyanidin (10, 25, 50µM) in combination with 
camptothecin (0.01µM) in   LoVo cells 
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Figure 15.  Cytotoxyc effect of delphindin and cyanidin (10, 25, 50µM) in combination with 
camptothecin (0.05µM) in   LoVo ADR cells.  
 
 
sample) of camptothecin when it was applied in combination with 25µM either 
delphindin or cyanidin in both cell lines that were used, speaking in favor of their 
probable synergistic effect.   
 
 
3.3. Apoptosis induction in LoVo and LoVo ADR cells by anthocyanidins 
 
To investigate the ability of anthocyanidins to induce apoptosis of cancer cells, LoVo and 
LoVo ADR were treated with delphindin and cyanidin at 100µM for 24h. Camptothecin 
at a concentration of 1µM in Lovo, and 5µM in LoVo ADR (approximately 25 times 
higher of its IC50  found for these cells) was used as a positive control. Both delphinidin 
and cyanidin induced apoptosis detected by morphological changes (cellular shrinkage 
and nuclear condensation) in the treated cell lines (Figure 16, 17).  
 
 
 
 
 
CP
T Mµ
de
l 1
0
CP
T+
de
l10 Mµ
de
l 2
5
CP
T+
de
l25 Mµ
de
l 5
0
CP
T+
de
l50
0
25
50
75
100
***
c
el
l g
ro
w
th
 
in
hi
bi
tio
n
 
(%
)
CP
T Mµ
cy
 
10
CP
T+
cy
10 Mµ
cy
 
25
CP
T+
cy
25 Mµ
cy
 
50
CP
T+
cy
50
0
25
50
75
100
***
ce
ll 
gr
o
w
th
 
in
hi
bi
tio
n
 
(%
)
 C 
 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
B D 
Figure 16.  Morphology of untreated (A) and treated LoVo cells (B. cells treated with 1µM camptothecin for 
12h, C. cells treated with 100µM delphinidin for 24h, D. cells treated with cyanidin 100µM for 24h.). The 
morphological changes in the nucleus chromatin were detected by staining with 5µg/mL DAPI, followed by 
examination on a   fluorescence microscope (40x) 
C 
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A 
B 
C 
D 
Figure 17.  Morphology of untreated (A) and treated LoVo ADR cells (B. cells treated with 5µM camptothecin for 
12h, C. cells treated with 100µM delphinidin for 24h, D. cells treated with cyaniding 100µM for 24h.). The 
morphological changes in the nucleus chromatin were detected by staining with 5µg/mL DAPI, followed by 
examination on a   fluorescence microscope (40x) 
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3.4. Delphinidin and cyanidin: anti- or pro-oxidants?  
 
To understand which mechanisms might lay the basis for anthocyanidins-induced 
citotoxicity in LoVo and LoVo ADR cells, the hypothesis that they, although well known 
as antioxidants, might behave as pro-oxidants in some cases was tested. The ability of 
delphinidin and cyanidin to scavenge/produce ROS in cells was examined following the 
kinetics of DCFH oxidation in CACO-2, LoVo and LoVo ADR cells. An external 
generator of peroxyl radicals (ABAP) was used in order to detect a possible antioxidant 
activity of the anthocyanidins in these cells.  
        The increase in fluorescence from DCF formation was inhibited by both delphinidin 
and cyanidin in CACO-2 cells in a dose–dependent manner as it demonstrated by the 
graphs (Figure 18) suggesting their antioxidant activity in these cells. Cyanidin was 
slightly more potent as a free-radical scavenger. 
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Figure 18.  Peroxyl radical-induced oxidation of DCFH to DCF in CACO-2 cells and the inhibition of 
oxidation by delphinidin and cyanidin (the curves shown in each graph are from a single experiment 
(mean±SD, n=3). 
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In LoVo cells, delphinidin at a concentration of 100µM slightly augmented ROS 
production whereas at concentration of 25 and 50µM did not show either anti- or pro-
oxidant properties. Cyanidin, on the other hand, moderately inhibits peroxyl-radicals 
produced by ABAP (Figure 19).   
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Figure 19.  Peroxyl radical-induced oxidation of DCFH to DCF in LoVo cells. Delphinidin (100µM) 
augments the oxidative effect whereas cyanidin (25µM) acts as an antioxidant (the curves shown in each graph 
are from a single experiment (mean±SD, n=3). 
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Figure 20. Peroxyl radical-induced oxidation of DCFH to DCF in LoVo ADR cells. Both delphinidin and 
cyanidin additionally augment the ROS levels induced by ABAP (the curves shown in each graph are from a 
single experiment (mean±SD, n=3).  
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Interestingly, in LoVo ADR cells, which were the most sensitive to the cytotoxyc action 
of the anthocyanidins, delphinidin and cyanidin act as strong inducers of free radicals in a 
dose-dependent manner (Figure 20). 
         The dose-response curves (calculated from the ratio of the area under the curve of 
the sample to that of the control) for inhibition/increase of ROS-induced DCFH 
oxidation, generated from the data presented by delphindin and cyanidin in Figures 18, 
19 and 20, are shown in Figure 21.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 25 50 75 100
0
10
20
30
40
50
cyanidin
delphinidin
      conc (µM)
CA
A
 
u
n
it
25 50 75 100
-20
-10
0
10
20
30
40
50 delphinidin
cyanidin
conc (µM)
 
 
 
 
 
 
 
 
 
 
 
 
 
CA
A
 
u
n
it
25 50 75 100
-100
-80
-60
-40
-20
0
delphinidin
cyanidin
conc (µM)
CA
A
 
u
n
it
A B 
C 
Figure 21. Dose-response curves for 
inhibition/increase of peroxyl radical-
induced DCFH oxidation by delphinidin 
and cyaniding in CACO-2 (A), LoVo 
(B) and LoVo ADR cells (C). 
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3.5. Effects of delphinidin and cyanidin on glutathione reductase activity   
 
Glutathione reductase (GR) is an enzyme involved in the glutathione cellular redox-state 
control pathway. It catalyzes the reduction of GSSG into GSH in a process that requires 
NADPH (that oxidizes during the reaction), thus helping to keep the ratio of GSH to 
GSSG very high, about 100:1. The hypothesis that anthocyanidin-pro-oxidant effect in 
LoVo ADR cells might be a result of their ability to inhibit glutathione reductase was 
tested here. A decrease of NADPH absorbance measured spectrophotometrically was 
used as an indicator of the glutathione reductase inhibition. 
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Figure 22. Changes in NADPH absorbance 
(measured spectrophotometrically at 340 nm) 
after 1h treatment with delphinidin and cyanidin. 
No significant changes were observed in CACO-2 
(A) and LoVo (B) cells. On the other hand, 
NADPH absorbance levels were significantly 
reduced in LoVo ADR suggesting an inhibitory 
effect of delphinidin and cyanidin on the 
glutathione reductase activity.  
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Indeed, in CACO-2 cells, in which both anthocyanidins showed strong antioxidant effect, 
the GR activity was not affected after the treatment. Neither delphinidin nor cyanidin 
showed any significant effect on the enzyme activity in LoVo cells. On the other hand, in 
LoVo ADR cells, in which both of them demonstrated pro-oxidant properties, a 
significant inhibition of the enzyme was detected suggesting that this might be a 
mechanism through which they induce pro-oxidant effects in these cells (Figure 22).  
 
 
3.6. Anthocyanidin-mediated modulation of intracellular GSH levels 
 
Since we demonstrated that delphinidin and cyanidin can change the GR activity in LoVo 
ADR cells, the next step was to see if and how that property of the anthocyaninidins 
affects intracellular levels of glutathione. The results that we obtained show that GSH 
levels in CACO-2 and LOVO cells remain unchanged after the treatment with the two 
anthocyanidins. However, in LoVo ADR cells GSH levels measured after the treatment 
with delphinidin and cyanidin were significantly lower when compared to untreated 
controls (Figure 23). This confirms our hypothesis that delphindin and cyanidin are able 
to modulate intracellular glutathione levels thus augmenting oxidative stress in LoVo 
ADR cells.  GSSG levels were hardly or not detectable in all three cell lines. 
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3.7. Delphinidin effects on doxorubicin accumulation in LoVo and LoVo ADR cells 
after short-term treatment 
 
Intracellular drug accumulation is a complex process including drug uptake into the cell, 
retention and distribution in the cell, and efflux from the cell. At any given time, the net 
uptake (accumulation) of a drug in cells is the difference between the amount of drug 
uptake and efflux. ABC transport proteins-mediating drug efflux decreases intracellular 
net drug uptake, and it causes cells to be drug-resistant. In an attempt to overcome the 
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Figure 23. Modulation of intracellular GSH 
levels by delphinidin and cyanidin. No significant 
changes were observed in CACO-2 (A) and LoVo 
(B) cells. On the other hand, GSH levels were 
significantly reduced in LoVo ADR cells (C). 
Intracellular GSH levels were calculated as 
nM/106 cells and presented as % compared to 
controls. 
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resistance that can develop due to ABC transport proteins overexpression, ABC 
transporters inhibitors have been developed. The rationale to develop inhibitors is 
straightforward; it is hypothesized that if the action of transport proteins (drug efflux) is 
blocked, it will result in an increased net uptake of drugs and greater clinical efficacy of 
chemotherapeutic agents in tumors overexpressing Pgp, MRP or BCRP. The main 
shortcoming of transport protein inhibitors was that they were not sufficiently active in 
vivo, and the doses required for inhibition of ABC transport proteins resulted in other 
pharmacological activity that led to unacceptable toxicity. 
In order to test if one of the possible mechanisms through which delphinidin increases 
cytotoxic effect of antineoplastic drugs involve its reaction and inhibition of ABC 
transporters, doxorubicin (a substrate of Pgp, MRPs and BCRP) intracellular 
accumulation was measured in untreated and delphinidin treated cells. The fluorescence 
characteristics of this drug were used to assess its intracellular concentration. Verapamil, 
a well-known Pgp inhibitor, was used as a positive control for Pgp inhibition. 
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Figure 24. Effect of delphinidin on doxorubicin accumulation in LoVo and LoVo ADR cells 
after 60min treatment: 1. cells treated with doxorubicin (25µM) alone for 60min; 2. cells 
pretreated with delohinidin (50µM) for 30min and treated with doxorubicin (25µM) for 
additional 60min; 3. cells treated with doxorubicin (25µM) and delphinidin (50µM) for 60min; 
4. cells pretreated with verapamil (50µM) and treated with doxorubicin (25µM) for additional 
60min 
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As it can be seen in the Figure 24, intracellular levels of doxorubicin remained high and 
independent of the treatment either with delphinidin or with verapamil in LoVo cells 
confirming that this cell line does not overexpress ABC transport proteins. However, in 
LoVo ADR cells the situation was dramatically different. Untreated cells had very low 
levels of doxorubicin, whereas in those treated with verapamil, the drug was accumulated 
at a concentration that was five times higher, suggesting overexpression of Pgp and 
confirming it as a reason, at least partly, for their greater resistance to antineoplastic 
drugs. However, the treatement with delphindin did not affect intracellular accumulation 
of doxorubicin.  
 
3.8. Delphinidin effect on doxorubicin accumulation in LoVo ADR cells after long-
term treatment 
 
Since delphinidin did non show any significant effect on the doxorubicin intracellular 
accumulation after a 60min treatment, it was hypothesized that a long-term incubation 
with low, non-cytotoxic doses of delphinidin might have different results. Indeed, after a 
five-week treatment with doses that ranged from 2.5-12µM, a significant increase in 
intracellular doxorubicin concentration was observed in cells treated with 10 and 12µM 
delphinidin (Figure 25).  
These results permitted a hypothesis that long-term treatment with non-cytotoxic doses of 
delphinidin might lead to changes in the expression of membrane transport proteins. 
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Figure 25. Effect of delphinidin on 
doxorubicin accumulation in LoVo ADR 
cells after 5-week treatment. Cells were 
treated with non-cytotoxic concentrations of 
delphinidin (2.5, 5, 10, 12µM) for 5 weeks, 
then were washed with PBS and incubated 
with doxorubicin for additional 60 minutes. 
Doxorubicin content was measured 
fluorimetrically. In cells treated with 10 and 
12µM delphinidin a significant increase in 
intracellular doxorubicin accumulation was 
observed 
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3.9. Pgp, MRP-1, and BCRP expression in LoVo ADR cells after five-week 
treatment with delphinidin 
   3.9.1. Immunocytochemistry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Pgp expression in LoVo ADR 
cells after a five-week incubation period 
with low doses of delphinidin: A. untreated 
cells; B. cells treated with 2.5µM 
delphinidin; C. cells treated with 5µM 
delphinidin; D. cells treated with 10µM 
delphinidin; E. cells treated with 12µM 
delphinidin. Cells treated with 10 and 
12µM delphinidin, showed decreased 
expression of Pgp after being incubated 
with a secondary antibody attached to 
FITC, and subsequently stained with 
DAPI. 
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Figure 27. MRP 1 expression in LoVo 
ADR cells after a five-week incubation 
period with low doses of delphinidin: A. 
untreated cells; B. cells treated with 2.5µM 
delphinidin; C. cells treated with 5µM 
delphinidin; D. cells treated with 10µM 
delphinidin; E. cells treated with 12µM 
delphinidin. Cells treated with 10 and 
12µM delphinidin, showed decreased 
expression of MRP 1 after being incubated 
with a secondary antibody attached to 
FITC, and subsequently stained with 
DAPI. 
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Figure 28. BCRP expression in LoVo 
ADR cells after a five-week incubation 
period with low doses of delphinidin: A. 
untreated cells; B. cells treated with 2.5µM 
delphinidin; C. cells treated with 5µM 
delphinidin; D. cells treated with 10µM 
delphinidin; E. cells treated with 12µM 
delphinidin. Cells treated with 10 and 
12µM delphinidin, showed decreased 
expression of BCRP after being incubated 
with a secondary antibody attached to 
FITC, and subsequently stained with 
DAPI. 
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To test the hypothesis that non-cytotoxic doses of delphinidin applied for a long period of 
time might exert inhibitory effects on transmembrane protein expression in LoVo ADR 
cells, the cells were treated as in the previous experiment and proceeded for 
immunocytochemical detection of Pgp, MRP-1 and BCRP. While the cells treated with 
2.5 and 5µM delphinidin did not show any changes in the expression of the proteins, a 
decreased plasma membrane expression of the transport proteins was observed in cells 
treated with 10 and 12µM delphinidin (Figure 26, 27, 28).  
 
 
3.9.2. Reverse transcriptase PCR 
 
In order to see if delphinidin is able to affect the ABC protein expression at the level of 
transcription, RNA was extracted from LoVo ADR cells treated with low doses of 
delphinidin for 5 weeks and RT PCR was performed (Figure 29).  
        The cDNA samples were diluted (1:10, 1:50, 1:100 and 1:200) and loaded in order 
to see how strong is the signal and at which dilution disappears. Nonquantitative RT-PCR 
analysis show that the signal in the treated samples promptly disappears as dilutions 
augment. On the other hand, in all control samples the signal is sustainable. This speaks 
in favour of our hypothesis that delphinidin, over long term treatment, could modulate the 
expression of ABC proteins at the level of their transcription and explains their lower 
membrane expression in the treated cells. However, these results are preliminary and 
need quantitative proof. 
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Figure 29. Delphindin treatment at low doses for 5 weeks leads to decrease in the ABC proteins 
mRNA levels; representative gels showing typical nonquantitative RT-PCR analysis of P-gp (A), MRP-
1 (B), and BCRP (C) mRNAs. In the treated cells, the signal disappears promptly as dilutions increase 
(from 1:10 to 1:200) whereas in the controls the signal is more sustainable. The order in which the 
samples were loaded was maintained same in all gels.  
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4. Discussion 
 
Anthocyanidins, such as delphinidin and cyanidin, have broad biological effects in 
antimutagenesis and anticarcinogenesis and have been hailed as useful natural agents for 
chemoprevention (95, 97, 99). They have been discussed in relation to their potential role 
in cancer therapy as well (90, 95, 128, 129). However, the molecular mechanisms 
underlying antitumor activity of anthocyanidins are poorly defined. The present study 
gives evidence that anthocyanidins delphinidin and cyanidin, aglycons of respective 
anthocyanins, have a strong cytotoxic effect in metastatic human colorectal cancer cell 
lines, LoVo and LoVo ADR, and that they are able to modulate the cytotoxicity of 
camptothecin, drug used in most colorectal cancer treatment regimes. Although well 
known for their antioxidant properties and lower toxicity in normal cells, delphinidin and 
cyanidin show strong prooxidant activity in the metastatic colon carcinoma cell lines. We 
show that anthocyanidins inactivate the glutathione antioxidant system thus promoting 
oxidative stress in these cells, which might be responsible for their proapoptotic activity. 
Moreover, when applied at low, non-cytotoxic concentrations over a long period of time, 
they also affect anticancer drug transport across cell membranes by modulating 
expression of certain transport proteins (ABC transporters).    
         Delphinidin and cyanidin were used in this study with the aim to investigate the 
potency of cytotoxic effect of anthocyanidins in the human colorectal carcinoma cells and 
the possible mechanisms for it. Three different cell lines were used: CACO-2 originating 
from primary tumor sites, and LoVo and LoVo ADR cells originating from colorectal 
carcinoma metastasis. LoVo ADR cells have been described as a cell line particularly 
resistant to chemotherapy due to overexpression of ABC transport proteins. Neither 
delphinidin nor cyanidin did show cytotoxic effect in CACO-2 cells, whereas both 
metastatic cells lines, LoVo and LoVo ADR, demonstrated sensitivity to the 
anthocyanidins. Interestingly, it seems that the sensitivity of these cells to the anticancer 
agent camptothecin and to the anthocyanidins is inversely proportional. The more the cell 
line is aggressive and resistant to camptothecin, the more it is sensitive to delphinidin and 
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cyanidin. This opens a question if delphinidin and cyanidin can modulate the cytotoxicity 
of camptothecin in the resistant cells when they are applied together. Indeed, both of 
them have been shown to act as strong inducers of camptothecin cytotoxicity. As it was 
reported earlier, anthocyanidins showed pro-apoptotic properties in human promyelocytic 
leukemia cell (108). Here we demonstrate that both delphinidin and cyanidin have 
apoptotic activity in LoVo and LoVo ADR cells. Thus, our findings suggest that 
delphinidin and cyanidin are cytotoxic per se in the metastatic colorectal cancer cells. 
Moreover, they also cooperate with the anticancer drug camptothecin, enhancing its 
potency to inhibit cancer cell growth. The cytotoxic activity of delphinidin and cyanidin 
is reached through their ability to induce apoptosis.  
         Antimutagenic and anticarcinogenic activity of anticyanidins is generally attributed 
to their antioxidant properties, as determined in various in vitro assays. Nonetheless, 
there are evidences that the apoptotic effect of anthocyanidins in cancer cells could be 
result of their ability to induce ROS accumulation in these cells. This has been 
predominantly demonstrated in leukemic cells (90, 108). Although this study has 
confirmed that delphinidin and cyanidin does posses the antioxidant activity in the 
primary tumor cell line CACO-2 (in which neither of the two showed cytotoxic effect), it 
finds that they actually cause ROS accumulation in the metastatic LoVo ADR cells that 
were particularly sensitive to their cytotoxic action. On the other hand, in LoVo cells in 
which their doses necessary to induce cytotoxicity are high, they do not show either anti- 
or pro-oxidant effect suggesting that there might be more than one mechanism through 
which anthocyanidins induce apoptosis. It is not quite clear why delphinidin and cyanidin 
have a different impact on the redox status in the metastatic and primary tumor cells.   
        One common biochemical change in cancer cells is the increase in reactive oxygen 
species generation. Previous studies suggest that most cancer cells are under oxidative 
stress associated with increased metabolic activity and subsequent production of ROS 
(130). The ROS increase is though to play an important role in maintaining cancer 
phenotype due to their stimulating effects on cell growth and proliferation (131), genetic 
instability (132), and scenescence evasion (122). However, high levels of ROS can also 
cause cellular damage, depending on the levels and duration of ROS stress (60). It has 
been hypothesized that neoplastic cells may be more vulnerable to oxidant stress because 
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they function with a heightened basal level of ROS-mediated signaling, which is required 
for the increased rate of growth. This makes them highly dependent on their own 
antioxidant systems to counteract the damaging effect of ROS and to maintain redox 
balance in a dynamic state. If this hypothesis is correct, then addition of an exogenous 
agent that increases ROS generation, or that decreases ROS scavenging capacity, would 
render a tumor cell highly vulnerable and may push it beyond the breaking point in terms 
of lipid peroxidation, DNA damage, and protein oxidation (133). On the other hand, 
normal cells may better tolerate such an intervention owing to their low basal ROS output 
and normal metabolic regulation.  
         The results obtained in this study could be, therefore, observed through the prism of 
the abovementioned. Namely, high ROS levels present in tumor cells are the direct result 
of increased metabolic activity in these cells. It is well known that neoplastic 
transformation modifies cellular energy metabolism (134). The extent of alteration in 
energy metabolism varies from one tumor cell type to another. The study conducted by 
Fanciulli et al. (135) investigated the energy metabolism of doxorubicin-sensitive (LoVo) 
and doxorubicin-resistant (LoVo ADR) colon cell lines. It has shown that the extent of 
alterations in energy metabolism strictly correlates with degree of drug resistance. That 
suggests that LoVo ADR, since having higher levels of energy-turnover compared to 
LoVo, have higher basal ROS levels than LoVo cells do. That could also permit us to 
hypothesize that CACO-2, since being a primary tumor cell line, have even lower 
metabolic activity in comparison to the both metastatic cell lines, and therefore lower 
basal ROS levels to deal with. Moreover, Fanciulli et al. show that the rate of aerobic 
lactate production is significantly higher in LoVo ADR than it is in LoVo cells, which 
makes their intracellular pH acidic. That could give an additional explanation why 
delphinidin and cyanidin induce oxidative stress only in LoVo ADR cells.  
         As members of the flavonoid group, anthocyanins share a C6C3C6 carbon skeleton. 
Anthocyanins exist in an aqueous phase in a mixture of essentially four molecular 
species, the concentrations of which depend on the pH (Figure 30). The flavylium cation 
(AH+) is formed and dominates at acidic pH 1−3; a carbinol pseudobase (B) is formed 
upon deprotonation and hydration at pH 4−5 and can further undergo ring opening to 
chalcones (CE and CZ). Finally, the flavylium cation can alternatively be transformed to 
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quinoidal-base isomers (A1, A2, and A3) through deprotonation and proton-transfer 
reactions and can undergo further conversion to quinoid anions. The relative amounts of 
cation (AH+), quinoidal forms (A1, A2, and A3), carbinol pseudobase (B), and chalcones 
(CE and Cz) at equilibrium vary with both pH and the structure of anthocyanins (136, 
137). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Borkowski et al. studied the radical scavenging capacity of common red wine 
anthocyanins and their respective aglycons (among which delphinidin and cyanidin) at 
various pH values, which are able to influence the different (de)protonation equilibria of 
these compounds in aqueous solution. They show that pH is a dominant factor in the 
Figure 30. Structural changes of anthocyanins in aqueous solutions based on transformations of red 
malvidin-3-O-β-glucoside flavylium cation into possible purple quinone methides (A1, A2, and A3), 
colorless carbinol pseudobase (B), and yellow chalcone forms (CE and CZ), at different pH (R1, R2 = 
OMe, R3 = glucosyl)  (taken from Borkowski T. et al. (137)). 
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ultimate radical scavenging capacity of both aglycons and glucosides, with increasing pH 
significantly increasing the capacity for radical scavenging and vice versa. Taken 
together, these facts could give a plausible explanation for the behavior of delphinidin 
and cyanidin in the cells that were used in this study. In LoVo ADR cells, which have 
been shown to have high metabolic activity and produce high levels of lactate which 
contributes to acidic pH, the anthocyanidins do not act as antioxidants since being 
protonated, but induce ROS accumulation. On the other hand, in LoVo cells, which have 
lower levels of basal metabolism compared to LoVo ADR and thus higher pH, they do 
not show significant changes in the redox state. However, in CACO-2, the cell line most 
similar to normal cells, they behave as strong antioxidants.       
        It is not yet clear how anthocyanidins promote oxidative stress in malignant cells. 
Feng et al. (90) demonstrated the increase of peroxides, but not superoxides, in leukemia 
cells treated with cyainidin-3-rutinoside. Therefore, one of the possible mechanisms for 
their pro-oxidant activity could be their reaction with the glutathione antioxidant system, 
which is involved in the scavenging of peroxides. There are yet a few reports on the 
possible role of flavonoids in the modulation of glutathione antioxidant system activity. 
Quercetin has been shown to decrease intracellular GSH content in human leukemia cells 
regulating its synthesis at the level of enzyme (γ- glutamylcysteine sinthetase) activity 
(128). It has been also hypothesized that flavonoid-induced GSH depletion in human lung 
epithelial tumor cells might be reached through potentiated MRP-1-mediated GSH efflux 
(89). Trachootham et al. suggested that β–phenylethyl isothiocyanate (PEITC), a 
naturally occurring phytochemical, induce ROS accumulation in transformed cells by two 
mechanisms: depletion of GSH by promoting its export and inhibition of glutathione 
peroxidase (GPX) enzyme activity (63). 
        An important role in the glutathione-associated redox cycles belongs to glutathione 
reductase (GR), an enzyme that reduces the oxidized form of glutathione, glutathione 
disulfide (GSSG), to reduced glutathione (GSH) able to react again with ROS. In this 
way, GR helps maintaining the antioxidative capacity of cells engaged in a wide variety 
of functions in which reactive oxygen species could pose a problem. Most of the studies 
which had the GR activity as a subject were orientated towards its role in plants. 
However, there are yet no reports on the role of anthocyanidins in regulation of the 
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glutathione reductase activity in human cell models. Here we show that delphinidin and 
cyanidin do interact with the glutathione antioxidant system in human metastatic colon 
cancer cells by inhibiting glutathione reductase (GR) activity. That ability of the 
anthocyainidins directly correlates with their capacity to induce ROS accumulation in 
treated cells. Indeed, in CACO-2 and LoVo cells, in which the anthocyanidins act as 
antioxidants or do not induce any significant changes in ROS levels, the activity of the 
enzyme remains unchanged after treatment. On the other hand, treatment of LoVo ADR 
cells with delphinidin and cyanidin leads to accumulation of ROS in these cells, and 
significantly reduces the activity of glutathione reductase. These results are in correlation 
with the result obtained in an in vitro study on the capacity of flavonoids to inhibit 
glutathione reductase (138). This study compared flavonoids from different classes and 
their ability to inhibit GR. It was shown that anthocyanidins (namely delphinidin and 
cyanidin) had the greatest potency for inhibition of the enzyme. Moreover, the inhibition 
was oxygen-dependent. The authors suggested a role for O2· in this oxygen-enhanced 
inhibition of GR by the anthocyanidins. One other study evaluated the relationship 
between antioxidant capacity of anthocyanins and their efficacy on the activation of 
phase II antioxidant (glutathione-dependent) and detoxifying (quinon-oxido 
metabolizing) enzymes in hepatocytes (139). It demonstrated a positive correlation 
between antioxidant capacity and promoting an effect on enzymatic activity in normal 
cells, including activated expression of glutathione-related enzymes, among which 
glutathione reductase.    
         We also demonstrate here that delphinidin and cyanidin are able to modulate 
intracellular glutathione levels. However, in CACO-2 and LoVo cells no significant 
changes in the total GSH levels are observed, and GSSG content was hardly or not 
detectable (which does not surprise since GSH:GSSG ratio is normally very high, 30:1 
(140), and GSSG levels thus low). On the other hand, both delphinidin and cyanidin have 
been shown to deplete intracellular glutathione levels in LoVo ADR cells. Since they 
demonstrated ability to inhibit GR, we expected to see elevated GSSG levels in these 
cells. Surprisingly, the levels of GSSG were hardly or not detectable. This could be 
explained with the fact that the affinity of MRP1 for GSSG is 10-100 times higher than 
the one for GSH (40). Since LoVo ADR cells over-express MRP1, GSSG “accumulated” 
 81 
after inhibition of GR might be pumped out immediately thus lowering the intracellular 
levels of total GSH and leaving the cell at the mercy of reactive oxygen species.  
        Taken together, all these observations suggest a dual role for anthocyanidins 
depending on cell type. In cells with lower basal metabolic rates such as normal cells but 
also, as it has been demonstrated in this study, tumor cells with low proliferation rate and 
low malignant potency (and thus similar to normal cells), they behave as free radical 
scavengers and protect them from oxidative stress. On the other hand, in highly 
malignant cells, with active metabolism and high intrinsic ROS production, which are 
often resistant to conventional anticancer drugs (such as LoVo ADR cells) delphinidin 
and cyanidin can act as pro-oxidants through reaction with the glutathione antioxidant 
system and inhibition of its components, such as glutathione reductase. ROS accumulated 
in that way can further trigger mitochondrial apoptotic pathway. Therefore, the intrinsic 
oxidative stress in cancer cells associated with oncogenic transformation could provide a 
basis for developing strategies to preferentially kill cancer cells through ROS-mediated 
mechanism, and compounds such as delphinidin and cyanidin, can be used to achieve 
such activity.  
         Apart from their role in modulation of cellular redox state, it was suggested that 
flavonoids could interact with ABC transporters as well. Some flavonoids were shown to 
inhibit P-gp-mediated transport processes by directly interacting with the vicinal ATP-
binding sites, the steroid-binding site, or the substrate domains (141), others like 
epicathechin from green tea, were shown to activate P-gp by a heterotropic allosteric 
mechanism (142) or to increase P-gp expression (143). A possible interaction of 
flavonoids with MRP1 was also studied. A number of studies revealed that many 
flavonoids can inhibit MRP1-mediated transport to a varying degrees (144, 145). The 
mechanism for flavonoid-MRP1 interactions may involve the binding to the nucleotide 
binding domains, and/or substrate binding sites (146). Some flavonoids, such as 
quercetin, myricetin, and apigenin, have been shown to stimulate GSH transport by 
MRP1 (53); therefore, depletion of cellular GSH, a cofactor for MRP1-mediated 
transport of chemotherapeutic agents, could also represent a potential mechanism for 
MRP1 inhibition by these compounds. Many flavonoids have been shown to interact with 
BCRP as well. Zhang et al. demonstrated that flavonoids were able to inhibit BCRP-
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mediated efflux of mitoxantrone in BCRP-overexpressing drug resistant human breast 
cancer cells and large cell lung carcinoma cells (147). Moreover, it was also shown that 
cytotoxicity of SN-38 (a metabolite of camptothecin derivative irinotecan) and 
mitoxantrone, which are both well-known BCRP substrates, can be substantially 
increased by the flavonoids genistein, naringenin, apigenin, kaempferol, in human 
leukemic K562 cells engineered to over-express BCRP, but not in the wild type K546. 
The expression of BCRP was not altered by this flavonoid treatment, and therefore, the 
sensitization of SN-38 and mitoxantrone by these flavonoids in most likely due to the 
inhibition of BCRP activity (148).  
         However, our study shows that delphinidin does not affect the doxorubicin (well-
known substrate for ABC transporters) transport in LoVo ADR cells. The intracellular 
concentration of the drug remains low after short term treatment, even when delphinidin 
is used at high concentrations (50µM). This suggests that there is no direct interaction 
between delphinidin and membrane transport proteins. On the other hand, when provided 
at low, non-cytotoxic concentrations (10 and 12µM) over 5-week period, delphinidin 
leads to a significant increase in intracellular doxorubicin concentration. Moreover, a 
decrease in the Pgp, MRP1 and BCRP expression can be noticed in these cells as well. 
That decrease seems to be a result of the delphinidin effect on the mRNA levels 
suggesting its possible role in modulation of ABC protein expression at the level of 
transcription.  
        In conclusion, this study demonstrates that delphinidin and cyanidin preferentially 
have a strong cytotoxic effect on cancer cells in advanced disease stage. Such highly 
malignant cells are often resistant to conventional chemotherapy, exhibit genetic 
instability and show significant increase in ROS generation due in part to the “vicious 
circle” in which ROS induce mutations leading to further metabolic malfunction and 
more ROS generation. We show that one of the possible mechanisms for this cytotoxic 
action could be the ability of delphinidin and cyanidin to augment oxidative stress in 
these cells, by inhibiting glutathione reductase and thus decreasing oxidant scavenging. 
However, other mechanisms for their pro-apoptotic action and subsequent cytotoxic 
effect can not be excluded, since they are able to inhibit tumor cell growth (although to a 
less extent) even without affecting cellular redox state. Additionally, long-term treatment 
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of the highly malignant and multidrug resistant cells with low concentrations of 
delphinidin can affect the expression of membrane transport proteins and increase their 
drug susceptibility. Efficacy of killing transformed cells warrants further investigation on 
use of anthocyanidins as sensitizers in cancer radio/chemo-therapy and synergetic effects 
with other anti-cancer compounds.   
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